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Abstract 
Transcranial Doppler ultrasound (TCD) is used for the assessment of cerebral blood flow 
velocity (CBFV) at the middle cerebral artery (MCA) with the assumption that diameter of 
the artery does not change. Thus, CBFV is equivalent to cerebral blood flow (CBF). The 
purpose of this thesis was determine if the MCA dilates during hypercapnia (HC) and/or 
constricts during hypocapnia (HO) in healthy young and older adults using 3T magnetic 
resonance imaging (MRI). We also determined how these changes in MCA cross-sectional 
area (CSA) influence estimates of CBF and cerebrovascular reactivity (CVR) from TCD in 
young and older adults. Lastly, we compared whether changes in MCA CSA mimic those at 
the internal carotid artery (ICA) as assessed with duplex ultrasound during HC and HO. For 
all studies, HC was induced with 6% carbon dioxide and HO with hyperventilation at 30 
breaths per minute, each for five minutes. T2-weighted sagittal images of the MCA were 
performed with MRI and collection of an image took approximately one minute. When 
assessing the peak response there was a significant increase in MCA CSA during HC and a 
decrease during HO. Using these MCA CSA values to calculate CBF resulted in a greater 
percent change during each protocol compared to CBFV. Changes in MCA CSA were also 
examined every minute over the five minute periods of HC and HO and significant increases 
were seen within the first minute of HC while decreases during HO were not evident until 
minute four. No changes in ICA CSA occurred during HC or HO. Using CBF rather than 
CBFV to calculate CVR resulted in a greater CVR for each protocol. Finally, when the 
response to HC was compared between young and older adults the increase in MCA CSA 
was reduced in older adults compared to young. Cerebrovascular conductance was also 
reduced in older adults compared to young during HC, while CVR was not different. In 
summary, the diameter of the MCA changes during manipulations of carbon dioxide and 
CBFV underestimates CBF and CVR. Also, CVR may not be the best metric to compare the 
vasodilatory response to HC between groups.               
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Chapter 1  
1 Introduction 
1.1 Overview 
In order to maintain cerebral function, blood flow is very tightly regulated to ensure 
adequate delivery of oxygen (O2) and nutrients and removal of carbon dioxide (CO2). 
Over a century of experimentation has contributed to our understanding of measurement 
and regulation of cerebral blood flow (CBF)(85). Despite these achievements, much work 
remains and is now potentially more important than ever as cerebrovascular function may 
play a role in the development of cognitive disorders such as dementia and Alzheimer’s 
disease (86). For example, in the U.S., the prevalence of Alzheimer’s disease is estimated 
to triple by 2050 (37). In this context, development of techniques to accurately quantify 
CBF and assess cerebrovascular function is vital.  
 Since its introduction in 1982 (2), transcranial Doppler ultrasound (TCD) has 
been used widely to quantify cerebral blood flow velocity (CBFV) during many 
experimental conditions including assessment of autoregulation, metabolic regulation of 
the cerebral vasculature by CO2 and O2, with exercise, and to assess disease status. With 
TCD, the middle cerebral artery (MCA) is most commonly insonated. The three main 
branches coming off of the circle of Willis including the anterior cerebral artery (ACA), 
middle cerebral or posterior cerebral (PCA) arteries can be insonated with TCD. 
Transcranial Doppler ultrasound is relatively inexpensive, has excellent time resolution, 
and is quite user friendly (103) and all of these factors have made it a commonly used 
tool. With TCD, since the vessel being insonated cannot be visualized, a key assumption 
is that the diameter of the insonated vessel does not change; this assumption leads to the 
idea that CBFV estimates CBF.  
Since the experiments of Kety and Schmidt (46, 47) the effect of “high CO2” or 
hypercapnia (HC) to increase CBF and “low CO2” or hypocapnia (HO) to decrease CBF 
have been measured and this response is termed cerebrovascular reactivity (CVR). 
Estimates of CVR have since been used to examine differences between clinical 
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populations in conditions such as migraine headache (54), diabetes (18) and transient 
ischemic attack (94), for example, and during healthy aging (107). Transcranial Doppler 
ultrasound is one method that is used to assess CVR and this estimate is used routinely to 
predict risk of stroke and transient ischemic events in individuals with carotid artery 
stenosis (32) and has been associated with all-cause mortality (79). Justification for the 
use of TCD to provide estimates of CBF during changing levels of end tidal CO2 
(ETCO2) come from magnetic resonance imaging (MRI) studies at 1.5T which suggested 
that the MCA diameter does not change during HC or HO (89, 96). However, with a 
higher resolution MRI (3.0T), MCA dilation can be observed during hypoxia (106). Since 
the cerebral vasculature is generally more sensitive to the partial pressure of CO2 (PaCO2) 
than the partial pressure of O2 (PO2) this could suggest that at a higher resolution a 
change in MCA diameter could be detected with MRI during changes in ETCO2. 
 Additionally, a change in diameter of the internal carotid artery (ICA), which is 
the main branch that leads into the MCA, during HO and HC has been documented (104). 
This is an important finding for two reasons: 1) If the ICA changes diameter during 
manipulations of ETCO2 it seems unlikely that the MCA diameter remains constant. 2) 
The diameter of the ICA can be determined using duplex ultrasound, which is a more 
readily available technology, whereas MRI is needed to examine MCA diameter. If 
changes in the ICA diameter mimic those that occur at the MCA then insonation of this 
vessel could prove useful for supplying a “correction factor” to estimate diameter 
changes at the MCA with changing ETCO2. Overall, this assumption that MCA diameter 
is constant while ETCO2 changes must be revisited now that advancements in MRI 
technology are available. This is important to establish first in a young and healthy 
population and then with a healthy aging and cardiovascular disease model since TCD is 
often used to estimate CVR in these groups.    
The overall objectives of this research were to quantify MCA diameter reactivity, 
and thereby determine whether or not TCD can adequately quantify CBF and CVR in 
healthy young and older populations. The working hypothesis is that the MCA constricts 
during HO and dilates during HC, leading to an underestimation of CBF and CVR with 
TCD. 
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Study 1. Cerebral blood flow velocity underestimates cerebral blood flow during 
hypercapnia and hypocapnia. 
Purpose: To determine whether the MCA constricts during HO and/or dilates 
during HC and to quantify the effect of such changes on CBF.  
Hypothesis: The cross-sectional area (CSA) of the MCA will change during HO 
and/or HC.  
Study 2. Heterogeneous patterns of vasoreactivity in the middle cerebral and 
internal carotid arteries. 
Purpose: To determine the time course of the change in CSA and flow of the 
MCA and ICA over 5 minutes of HC and HO in healthy individuals and to study 
the contributions of MCA CSA data to the estimation of CVR values. 
Hypothesis: The change in CSA during HC and HO will lead to an 
underestimation of CVR as traditionally calculated with CBFV. Additionally, 
changes in ICA CSA will mimic changes in the MCA during HO and HC.  
Study 3. Role of the middle cerebral artery and grey matter volume in 
cerebrovascular changes with healthy aging.   
Purpose: To assess the effect of healthy aging on MCA vasodilation, 
cerebrovascular reactivity, and cerebrovascular conductance during HC and to 
normalize these indices to grey matter volume.  
Hypothesis: The older adults will have less of a vasodilatory response at the MCA 
compared to young controls and therefore have decreased CVR and CVC. 
Cerebral blood flow will be similar between young and older adults when 
normalized to grey matter volume.    
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1.2 Anatomy of the Cerebral Vasculature 
The brain is supplied by four major arteries which eventually converge to form the circle 
of Willis. This system is unique to the brain, as opposed to other organs, in that blockade 
of one of these major arteries does not necessarily mean that adequate perfusion cannot 
be maintained to the entire brain. Outside of the cerebral circulation, large arteries are 
generally thought of as conduit vessels and arterioles as the regulator of vascular 
resistance. In the brain, the larger vessels have more involvement in regulating 
cerebrovascular resistance (22). For example, moving from the aorta to the pial arteries 
results in a 50 to 60% reduction in systemic pressure, and estimates suggest that larger 
cerebral arteries contribute anywhere from 20 to 60% of cerebrovascular resistance (22, 
38).   
Posteriorly, the two vertebral arteries unite intracranially to form the basilar artery 
(Figures 1.1 and 1.2). More anteriorly, the carotid arteries contribute the majority of 
blood supply to the brain, with each contributing approximately 40% to total perfusion 
(21). From the common carotid artery there is a bifurcation and the external carotid artery 
supplies blood to the facial region while the ICA enters the cranial cavity (Figure 1.1) and 
divides into four major branches: the ACA, MCA, anterior choroidal, and the posterior 
communicating arteries. From the ICA on each side the anterior cerebral arteries are 
joined by the anterior communicating artery and run parallel to one another to form the 
rostral portion of the circle of Willis.  The posterior communicating arteries are the 
bridge between the rostral (carotid) circulation and the caudal (basilar) circulation and 
with the basilar artery forms the caudal portion of the circle of Willis (Figure 1.2). 
Interestingly, this “normal” layout of the circle of Willis was observed in just over half of 
human brains in a large sample so this anatomical layout is actually quite variable (4). 
 The largest branch originating from the basilar artery is the PCA which supplies 
the inferior and medial aspects of the temporal and occipital lobes (Figure 1.2)(21). The 
MCA supplies the lateral aspects of each cerebral hemisphere whereas the ACA supplies 
the medial aspects of the frontal and parietal lobes (21). From these main arteries there is 
continual branching until the final superficial pial arteries penetrate into the brain matter 
and are aptly named penetrating arteries (14). These arteries are surrounded by the 
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Virchow-Robin space and when this space disappears the arterioles are then known as 
parenchymal and become almost completely surrounded by the end-feet of glial cells 
known as astrocytes. Astrocytes play a role in the regulation of CBF and will be 
discussed further below (14).   
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Figure 1.1: The internal carotid and vertebral arteries: right side. Reproduction of a 
lithograph plate from Gray's Anatomy from the 20th U.S. edition of Gray's Anatomy of 
the Human Body, originally published in 1918. 
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Figure 1.2: The arteries of the base of the brain. The temporal pole of the cerebrum and a 
portion of the cerebellar hemisphere have been removed on the right side. Reproduction 
of a lithograph plate from Gray's Anatomy from the 20th U.S. edition of Gray's Anatomy 
of the Human Body, originally published in 1918. 
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1.3 Quantification of Cerebral Blood Flow and Transcranial 
Doppler Ultrasound 
Blood flow can be described by Poiseuille’s law [1] and this law applies during laminar 
flow with Newtonian fluids in a rigid tube, where flow (Q) is proportional to the pressure 
change across the system (ΔP) and the radius of the tube to the fourth power (r) and is 
inversely proportional to the length of the tube (L) and viscosity of the fluid (μ). Within a 
system, during acute changes in Q it is generally assumed that μ and L do not change; 
thus, Q is determined by the pressure change and the change in r. The effect of r can also 
be thought of in terms of vascular resistance where Q is inversely proportional to 
resistance.  
[1]                                                  
𝑄 =  
𝛥𝑃𝜋𝑟4
8𝜇𝐿
 
 Early on, most techniques developed to measure CBF relied on inert or 
radioactive tracers and a modification of the Fick equation which states that the amount 
of a tracer taken up by a tissue per unit time is equal to the product of the blood flow 
through an organ and the arteriovenous difference of the tracer (16). Kety and Schmidt 
(1946) were the first to use this principle with inert nitrous oxide gas as the tracer (46). 
Since this time other non-invasive imaging techniques have been established and are used 
widely.  
1.3.1 Transcranial Doppler Ultrasound 
The methods discussed above that rely on the Fick equation give an overall estimation of 
CBF for the brain as a whole. In contrast, transcranial Doppler ultrasound (TCD) 
measures CBFV at the larger vessels that supply the brain with blood. The premise of 
Doppler ultrasound is that an ultrasound beam with a known emitted frequency makes 
contact with a moving red cell and this contact changes the frequency returning to the 
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receiver. Using this frequency information, which is known as the Doppler shift, the 
velocity of the red cell can be calculated using the following equation: 
[2]                                                                  
𝑣 =
𝑓𝑑 ∙ 𝑐
2𝑓𝑡 ∙ 𝑐𝑜𝑠 𝜃
 
Where v is velocity, fd is the detected frequency, c is the velocity of a sound wave 
through tissue, ft is the transmitted frequency and θ is the angle of insonation (27). This 
principle was applied to the cerebral circulation as early as 1965 (68), during surgery or 
in children with open fontanels with the conventionally applied frequency of 5 to 10 MHz 
(2). This technique was modified to be usable in adults using a frequency of 2 MHz 
where there is less attenuation of signal by bone and soft tissues. This allows TCD to be 
applied at windows of the skull where bone is thinner. The most commonly used window 
is known as the transtemporal window of the temporal bone where TCD can be used to 
examine CBFV in the ACA, MCA, and PCA which are the three main arteries off of the 
circle of Willis (2). For the MCA, the first branch off of the circle of Willis (the M1 
segment) is most commonly insonated and this is also the case for the A1 branch of the 
ACA (77). For the posterior circulation, two portions of the PCA can be insonated 
including P1, which is the segment between the basilar artery and the posterior cerebral 
collateral artery, and P2, which is the portion distal to the posterior cerebral collateral 
artery (103). The majority of studies examining the PCA focus on the P1 segment (78, 
104). Knowledge of each of the three cerebral arteries average flow velocity, direction of 
flow, and average depth are used to locate each vessel during a routine TCD examination 
(103).     
 Quantification of CBF is possible with duplex ultrasound of the extracranial 
arteries of the neck as the Doppler signal is used to quantify CBFV and B-mode images 
are used to determine arterial diameter from which CBF can be calculated (61, 104). With 
TCD B-mode imaging can be done but it appears to overestimate arterial diameter 
compared to MRI measurements (106). Often, users of TCD assume that CBFV is 
equivalent to CBF and this is based on the belief that the diameter of the intracerebral 
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arteries (mainly the MCA) is constant. This assumption has been examined with MRI 
during manipulations of ETCO2 and via direct observation during craniotomy. Two 
studies have examined MCA diameter at 1.5T during hyperventilatory HO and found no 
difference in MCA diameter during a decrease from baseline ETCO2 by ~13 mmHg (89, 
96). Serrador et al. (2000) also looked at HC to an ETCO2 of ~45 mmHg and found no 
change in diameter (89). In this study, at 1.5 T, the resolution of the magnet was reported 
to be 0.47 mm. It is possible that changes in MCA diameter were not large enough to be 
detected at this resolution. When ETCO2 was manipulated during craniotomy, the 
diameter change was 1.7% with a sample size of three (28).  
Together, these findings described above led most researchers to interpret CBFV 
as CBF. However, conflicting evidence has been presented. For example, simultaneous 
recordings of MCA CBFV and venous outflow velocity from the sphenoparietal sinus 
during HC to ~55 mmHg indicated that venous outflow was higher than MCA CBFV 
which indicates dilation at the MCA (97). Also, when comparing 133Xe clearance 
estimates to TCD CBFV during HC with 4 and 6% CO2 (in O2) CBF determined with 
133Xe clearance was greater than TCD CBFV estimates, inferring vasodilation (15). 
Lastly, Doppler power can be used to estimate vessel CSA based on the derivation of an 
equation by Arts and Roevros (1972) used for determining blood flow (5). At the MCA, 
when Doppler power was used as an index of CSA during hypercapnic hypoxia (end tidal 
PO2 was 50 mmHg and ETCO2 was 8.5 to 9.5 mmHg above baseline), at the end of the 
stimulus, a significant increase in Doppler power was noted which the authors suggest is 
indicative that vasodilation had occurred (80). Notably, in this study neither HC or 
hypoxia alone had an effect on Doppler power (80). Also, comparison of Doppler power 
to vessel area in a flow phantom has raised questions as to whether power-based 
estimates of CSA are justifiable in vivo (19).  Overall, the fact that some of these findings 
are inconsistent seems to indicate that the question of whether or not the MCA diameter 
is constant during HC and/or HO needs to be revisited.  
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1.4 Magnetic Resonance Imaging 
In the context of this thesis, MRI is used for quantification of CBFV, determination of 
MCA CSA, and estimation of brain volume so the focus will be on details relevant to 
these techniques.   
 In the simplest terms, the basis for the MRI signal are the protons that lie within 
the abundant hydrogen atoms throughout the human body. Hydrogen nuclei intrinsically 
possess a nuclear spin that gives rise to a magnetic field for each proton. Normally these 
spins are pointing randomly but within the external magnetic field of the MRI they are all 
oriented in the same direction to form the net magnetization. The net magnetization is a 
vector with a transverse component (perpendicular to the magnetic field) and a 
longitudinal component (parallel or antiparallel to the magnet field). When a person is 
placed within the MRI, the transverse components cancel out so there is no net transverse 
magnetization but a longitudinal component is generated because there are more spins 
parallel to the field than antiparallel. However, no signal is actually generated until these 
spins are tipped away by what is called a radiofrequency pulse (usually by 90˚ to tip 
magnetization from fully longitudinal to fully transverse) from their original orientation; 
the recovery to their equilibrium state is where the MRI signal comes from. When 
magnetization is in the transverse direction the spins produce an oscillating electric 
current so signal is produced. After the spins have been tipped, the recovery of the 
longitudinal magnetization is described by a time constant known as T1. In the transverse 
direction, the spins lose coherence (are out of phase with one another) and the 
magnetization decays; this process is described by the time constant T2. An image is 
formed because different types of tissue have different T1 and T2 values (83). In T2-
weighted images tissues with long T2 values give the largest signal intensity so they 
appear to be bright. Fluids have the longest T2 while water-based tissues have longer T2 
values than fat-based tissues (Figure 1.3)(65). In images with predominantly T1 contrast, 
long T1 tissues give the weakest signal so in this case, the brightest pixels are associated 
with short T1 values. Any tissues with more water (and thus more protons) will appear 
dark and this type of scan is useful for showing anatomy (Figure 1.3) (65). 
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Figure 1.3: Sagittal image of the spinal column with T2 contrast (left side) and T1 
contrast (right side). Image courtesy of GE Healthcare. 
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Phase contrast (PC) imaging can be used to determine CBFV and was first 
described by Moran in 1982 (70). This type of MRI is based on the principle that applied 
magnetic gradients introduce a phase shift in moving protons that is proportional to fluid 
velocity (9). With PC MRI two acquisitions need to be performed because the phase of 
the signal can depend on many factors. Therefore,  it is necessary to collect one 
acquisition with a pulse sequence that is relatively insensitive to flow followed by one 
that is sensitive to flow over a particular range of velocities so that the two acquisitions 
can be subtracted. This should remove the effect of any dephasing due to other factors. 
The phase is unchanged for any protons that are not moving, thus the subtraction also 
suppresses any signal from background tissue (102). The maximum measurable velocity 
is a parameter selected by the operator, known as the encoding velocity (Venc), which 
corresponds to a phase shift of 180° (69).  
 Estimates of CBFV derived from TCD have been compared to PC derived 
estimates, although few studies have looked at agreement between the two modalities 
beyond calculation of a correlation coefficient which is useful for detection of random 
error but does not detect systematic biases (62). Baledent et al. (2006) found small to 
moderate correlations between PC and TCD for peak systolic and end diastolic velocities 
in the MCA and absolute values for TCD were higher than for PC (9). Valdueza et al. 
(1997) also reported higher values of CBFV at rest and during hyperventilation with TCD 
(96). In the only examination to date looking at CVR to HC (from 40 mmHg at baseline 
to 45 mmHg) with PC MRI and TCD it was again reported that CBFV and CVR values 
derived from TCD were slightly higher and proportional bias was present where there 
was a larger difference between the two modalities at higher velocities (57). It remains to 
be seen how TCD and PC MRI may compare when velocities are examined over a wider 
range of ETCO2.   
 MRI can also be used to examine structural properties of the cerebral blood 
vessels with angiography (magnetic resonance angiography). Magnetic resonance 
angiography relies on changes in the signal due to the flow of blood through or within the 
image plane. If, after the 90˚ pulse, another 180˚ pulse is applied then an image with T2 
contrast can be generated that has what is known as “black blood contrast” where the 
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blood appears dark and there is good contrast between the blood vessel walls and the 
blood (83). In contrast, if this 180˚ pulse is not applied, then the signal from flowing 
blood is visible and appears bright. This is the basis for time-of-flight magnetic resonance 
angiography (12). 
 Brain volume quantification is a technique used to detect structural differences of 
different brain tissues (grey matter, white matter, etc.) while discounting differences in 
positioning and larger scale differences in volume (6). The steps for determination of 
brain volume involve spatially normalizing a T1-weighted image of an individual brain to 
the group template. This process is a registration so that local areas stretch and compress 
with respect to one another to match the template image. The image is then segmented 
into tissue classes (gray matter, white matter and cerebrospinal fluid) and smoothed. This 
type of analysis has been applied to many areas of research. For example, the negative 
linear association grey matter volume and age has been characterized with this 
methodology (31).  
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1.5 Regulation of Cerebral Blood Flow 
The regulation of CBF is complex and is dependent on many factors including the 
perfusion pressure of the brain, arterial blood gases, metabolic factors involved with 
neurovascular coupling, and the autonomic nervous system (105).   
1.5.1 Carbon Dioxide 
It is well established that alterations in PaCO2 have an effect on cerebral vessels that is 
unique to the cerebral circulation (3). Increased PaCO2 results in decreased tone in all 
cerebral vessels with the smaller vessels being most responsive. Hypocapnia causes a 
similar increase in tone in cerebral vessels of all sizes (100). Hypercapnia produces an 
increase in CBF that was first reported to be approximately 75% during inhalation of 5 to 
7% CO2 (47). Conversely, a decrease in PaCO2 causes a decrease in CBF which was first 
documented to be 32% during active hyperventilation (46). In general, during HO CBF 
decreases 2 to 3% per mmHg decrease in PaCO2 to a minimum level of ~10 to 15 mmHg. 
During HC the increase in CBF is approximately 3 to 4 % per mmHg increase in PaCO2 
with its highest level at 10 to 20 mmHg above baseline (13). It was originally unclear 
whether PaCO2 itself was the stimulus for the change in CBF or whether the 
accompanying pH change initiated the response. Human studies ruled out the effect of 
arterial pH on vessel diameter (36, 53). Direct observation of pial arterioles in an 
anesthetized cat model have shown that the effect of CO2 is mediated by a change in pH 
of the extracellular fluid (cerebrospinal fluid) rather than a change in PaCO2 (51).  
The mechanism through which CO2/pH affects vessel tone is not entirely clear 
and this is probably due to redundancy in the regulatory mechanisms. An inhibitory effect 
of protons on voltage dependent calcium channels has been suggested whereby their 
activation prevents calcium entry into the vascular smooth muscle cell (101). 
Additionally, potassium (K+) channels have been proposed to play a role where their 
activation leads to hyperpolarization of the membrane, inhibition of calcium channels and 
vasodilation (73). Based on animal work, four types of K+ channels have been identified 
on cerebral vessels including inward rectifier K+ channels, delayed rectifier K+ channels, 
ATP-sensitive K+ channels, and calcium-sensitive K+ channels (50). Of these, ATP-
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sensitive K+ channels and calcium activated K+ channels likely play a major role (59). In 
animal studies, only combined inhibition of ATP-sensitive K+ channels and calcium 
activated K+ channels abolished hypercapnic vasodilation (59).  
In addition to a direct action on various ion channels, it is possible that CO2/pH 
exerts effects on cerebral vessels through vasoactive mediators. Nitric oxide (NO) likely 
plays a role in the flow response to HC since its blockade reduces the response (88, 99). 
Exogenous administration of a NO donor also increases the response to HC and 
diminishes the response to HO in humans (55). It appears that the source of NO, at least 
in a rodent model, is neuronal NO synthase, rather than the endothelium (58). However, 
there are also contradictory data that minimize the role that NO plays on CVR to CO2. 
Ide et al. (2007) reported that blockade of NO had no effect on the CBFV response to HC 
(42). It is possible that this is due to compensatory dilatory mechanisms that are 
upregulated when NO is blocked. Additionally, when nitrite and nitrate levels were 
examined (as surrogate estimates of NO), along with CVR, there was no correlation 
between the measurements (66). 
Evidence from pigs suggests that prostenoids may play a permissive role during 
HC-induced increases in flow but on their own they are not likely the necessary mediator 
for vasodilation (56). Also, in humans, administration of the cyclooxygenase inhibitor 
indomethacin, reduces the CBFV response to HC (10).  The conclusion from the bulk of 
this evidence is that we have some ideas as to how CO2 exerts its effects on the cerebral 
circulation but there are still many questions that remain unanswered.  
The vasoactive response in the brain to HC and HO has been utilized to estimate 
CVR and characterize cerebrovascular health. As stated previously, CVR is the change in 
CBFV or CBF to a change in PaCO2 and is generally quantified as the absolute or percent 
change in CBF (or CBFV) per change in PaCO2 (or ETCO2). Cerebrovascular reactivity is 
thought to be an indicator of overall cerebral health and decreased CVR is associated 
with several pathological states including ischemic stroke in those with carotid occlusion 
(92), sleep-related disordered breathing (71), hypertension (90), multiple sclerosis (63), 
Alzheimer’s disease (67), preeclampsia (87), and mortality in general (79).  
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Commonly, HO CVR is assessed during hyperventilation that reduces PaCO2. 
Alternatively, within the literature there are varying methodologies employed to increase 
PaCO2 including rebreathing (30), breath holding (45, 81), inhalation of 2 to 6% CO2 in 
air (10, 84), inhalation of 5% CO2 in 95% O2 (referred to as carbogen) (44), and 
administration of acetazolamide (98), which increases PaCO2 by inhibiting the enzyme 
carbonic anhydrase. Benefits and drawbacks of each of these are summarized in a review 
by Fierstra et al. (2013)(23) and the authors conclude that the best option is CO2 as a 
stimulus to examine CVR. 
1.5.2 Blood Pressure 
In general, cerebral perfusion pressure can be defined as the difference between mean 
arterial pressure (MAP) and intracranial pressure. For decades, students of physiology 
have been taught that CBF is protected against changes in MAP over the pressure range 
of approximately 60 to 150 mmHg and this concept is known as cerebral autoregulation 
(CA). Autoregulation can be examined in terms of the steady state relationship between 
CBF and MAP over minutes or hours and this is known as static CA (105). Alternatively 
the capacity of the cerebrovasculature to regulate the pressure-flow relationship to 
transient changes in MAP over several seconds or heart beats is known as dynamic CA 
(105). Based on an amalgamation of studies in patients, the concept of autoregulation was 
developed and only recently has it been questioned since studies in healthy humans do 
not support a system where CBF is completely protected against fluctuations in MAP 
(61). Not until technology was available in the 1980s to examine beat-by-beat 
measurements of MAP and CBF was it possible to examine more transient effects of 
MAP on CBF. Aaslid (1989) developed a thigh cuff method where occlusion of the thigh 
with rapid cuff release induced transient hypotension and it was observed that CBFV 
tracked the drop in MAP but recovered more quickly (1). This finding with others led to 
the development of the concept that CA acts as a high pass filter where higher frequency 
BP fluctuations are transferred to the cerebral circulation whereas the circulation is 
buffered against slower changes in MAP (108). 
 It should be noted that static versus dynamic CA are experimental rather than 
physiological classifications and it is likely that the mechanisms for static and dynamic 
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CA are similar. A close matching in the percent change in cerebrovascular resistance to 
slower, drug-induced changes in pressure and those that occur during the drop in MAP 
during thigh-cuff release has been described (95). The mechanisms through which 
cerebrovascular resistance is modified to maintain cerebral perfusion pressure are unclear 
at this time but likely include a combination of neurogenic, myogenic and possibly 
endothelial responses (93, 105). Interestingly, based on animal studies, it has been 
estimated that larger cerebral arteries contribute anywhere from 20 to 60% of 
cerebrovascular resistance at rest (22, 38). 
   Additionally, it is important to remember that factors like BP and CO2 do not 
exert their effects on the cerebral blood vessels independently. There is an interplay 
between the role of MAP and CO2 on the cerebral vasculature. This was first established 
in dogs where animals with a MAP of 100 mmHg had a less pronounced reaction to HC 
and HO than normotensive animals and at a MAP of 50 mmHg there was no change in 
CBF with HC or HO (35). Also, using CO2 as a stimulus to examine CVR may also 
increase systemic MAP and possibly perfusion pressure. Battisti-Charbonney et al. 
(2011) observed that below a threshold ETCO2, MAP changed little, but above this, MAP 
increased linearly with ETCO2 (11). Therefore, it is important to report cerebrovascular 
conductance (CVC) in an attempt to account for the effect of MAP changes during a 
CVR test.  
1.5.3 Neural Control 
The cerebral vessels are densely innervated and the sources of innervation differ 
depending on the location of the vessel. The larger blood vessels that run along the 
surface of the brain are said to be innervated extrinsically by the superior cervical 
ganglion, the sphenopalatine and otic ganglia, and the trigeminal ganglion (33). The 
superior cervical ganglion provides sympathetic innervation and releases norepinephrine 
and neuropeptide Y. The sphenopalatine and otic ganglia are responsible for 
parasympathetic innervation and releases vasoactive intestinal polypetide, NO, 
acetylcholine, among others. Lastly, the trigeminal ganglion is a source of sensory nerves 
that contain calcitonin gene-related polypeptide, substance P, neurokinin A, and others 
(33). The role of extrinsic sympathetic innervation in the brain is somewhat unclear as the 
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results of blockade studies in humans have been equivocal (41, 75). In contrast, 
ganglionectomy in patients with pathological conditions has resulted in increased CBF in 
the majority of studies (43, 91) though it is unclear how these findings may apply in a 
healthy population (48). In addition, the general consensus based on the body of literature 
suggests that sympathetic innervation may serve as a protective mechanism to shift the 
autoregulatory curve to higher pressure. This mechanism would protect the brain against 
increased pressure with sympathetic activation (33). For example, when norepinephrine 
was infused to raise pressure the change in cerebrovascular resistance that occurred was 
not present when phentolamine, which is a non-selective α-receptor blocker, was infused. 
Additionally, CBFV increased when norepinephrine and phentolamine were infused 
together indicating that CA was impaired (49). 
 As pial arteries enter the brain cortical tissue they lose this extrinsic nerve supply 
and receive inputs from neurons within the brain itself and this is termed “instrinsic 
innervation.” These smaller vessels receive nerve afferents from areas such as the locus 
coreuleus, raphe nucleus, and basal forebrain (14). However, this innervation does not 
interact directly with the vessel but is instead in contact with astrocytes surrounding the 
blood vessel (14). The best studied pathways involved in intrinsic innervation include 
release of acetylcholine from the nucleus basalis, norepinephrine from the locus 
coeruleus, and serotonin from the raphe nucleus (33). Receptors for these 
neurotransmitters are located on both astrocytes and on smooth muscle and/or endothelial 
cells of blood vessels (33). Complete description of these pathways is beyond the scope 
of this review but it should be noted that literature in this area focuses, out of necessity, 
on animal models and in some cases on brain slices. In this type of experimental set-up 
blood vessels are not pressurized and do not have intraluminal flow (33). This is a 
valuable experimental design to answer some questions about intrinsic innervation but 
applicability to the intact human cerebrovasculature is unclear.     
1.5.4 Metabolic Control 
Within the brain, blood flow increases to areas that are neuronally active and this 
relationship is termed neurovascular coupling. The distribution of CBF is coordinated to 
increase when activity in a certain brain region increases and this response is known as 
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functional hyperemia. The hyperemic response occurs within seconds and is very specific 
to the region that is neuronally active (17, 74). There is a close association between 
neurons, astrocytes and blood vessels within the cortex and together, these three 
components comprise the neurovascular unit. Functionally, this association allows 
delivery of substrates to support neuronal activation and removal of metabolic by-
products (40).  
The mechanisms that are involved neurovascular regulation are still a topic of 
study but it is clear that there is involvement by neurons, astrocytes and vascular cells 
(40). Initially, it was proposed that a reduction in glucose or oxygen triggered by 
neuronal activation may trigger the blood flow response. However, further research 
indicated that it is likely synaptic signaling and not an energy deficit that triggers the flow 
response (7). There are several chemical mediators that have been proposed to be 
involved in stimulating the functional hyperemic response and this list includes ions, 
neurotransmitters, vasoactive factors that are released in response to neurotransmitters, 
and metabolic by-products (29). However, in blockade experiments, inhibiting one 
candidate mediator does not completely inhibit the response which indicates that there 
may be mechanistic redundancy or that some combination of the proposed mediators are 
involved in the response (40). One mechanism that is fairly well established to play a role 
in the hyperemic response is activation of glutamate receptors through synaptic 
transmission that initiates release of NO (39) and increases calcium in astrocytic end-feet 
that leads to release of other vasoactive mediators including prostenoids (40), of which 
some derivatives lead to vasodilation while others cause constriction (39). Which 
pathway predominates at any given time remains unclear but is likely regulated by 
another mediator such as lactate, adenosine, or the level of oxygen (39). From the local 
area where there is an up regulation in flow associated with neuronal activation upstream 
arteries also dilate to prevent a drop in microvascular pressure and avoid a ‘steal’ from 
adjacent areas (22). Overall, the mechanisms involved in neurovascular coupling remain 
unclear and require further study, especially in humans. The issue is further complicated 
because the mechanisms of functional hyperemia may differ from one brain location to 
another (40). For example, in the cerebellum CBF increases are highly dependent on NO 
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synthase but in the somatosensory cortex NO synthase-related mechanisms play a less 
prominent role (20).    
1.6 Cerebrovascular Reactivity and Aging 
As mentioned previously, CVR is decreased with many pathological conditions. 
However, the evidence related to healthy aging and CVR is mixed with some studies 
reporting that CVR is reduced with healthy aging (10, 25, 60), maintained (26, 72), 
increased (109), or different between sexes (44, 64). These differences likely are due to a 
number of factors including the age range of the subject pool, the stimulus used to assess 
CVR, sex differences, and possibly the way that the data are presented.  
A large scale epidemiological study was conducted by Bakker et al. (2004) that 
examined CVR in adults grouped by decade up until the age of 90 reported a 0.08% per 
mmHg decrease per year (8). Therefore, studies that use an older population are probably 
more likely to find a difference in CVR compared to a young group. Additionally, the 
literature on CVR is complicated by the use of 5% CO2 in 95% oxygen (known as 
carbogen) as a stimulus (8, 44, 60). This is problematic because a constrictive effect from 
the hyperoxia may counteract vasodilation due to HC (24). For example, when CVR was 
determined by two imaging methods, using the blood oxygen level dependent signal and 
arterial spin labelling, there was agreement between methods when CO2 in air was the 
stimulus and agreement with blood oxygen level dependent imaging carbogen estimates 
of CVR. However, the CVR values determined with arterial spin labelling and carbogen 
did not agree with other estimates (34). Lastly, when CO2 in air is used as the stimulus, 
different percentages of CO2 have been used in the literature ranging from 2% to 7% (10, 
72, 76, 82, 107). This difference makes comparison between studies more challenging.    
 Some studies have reported that there are sex differences in CVR. Bakker et al. 
(2004) examined CVR in older adults aged 55 years and older and found that CVR was 
greater in men (8). Additionally, declining CVR in women with age but no effect in men 
has been reported (44). Similarly, Matteis et al. (1998) reported that CVR, as assessed by 
the breath-holding index, was lower in post-menopausal women compared to younger 
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premenopausal women and young and older men (64). Significant differences in CVR 
have also been reported across the menstrual cycle (52) yet very few studies take this into 
account when choosing young female subjects.       
The reporting of CVR in terms of absolute values or percent change further 
complicates study findings. For example, Oudegeest-Sander et al. (2014) examined CVR 
in young, elderly, and older elderly groups and found no difference in CVR expressed in 
relative terms but a difference in absolute values (76). Since there is no standardized 
metric that is preferred then both absolute and relative CVR should be presented. Lastly, 
the majority of studies described here have utilized TCD, and therefore, have measured 
CBFV not CBF. If the MCA dilates during HC and/or constricts during HO to a different 
extent in young and older subjects then using CBFV alone may disguise any differences 
between the groups. In summary, the question of whether or not aging is related to 
diminished CVR should be revisited due to the limitations in the previous research 
described above. 
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Chapter 2 
2 Cerebral blood flow velocity underestimates cerebral 
blood flow during modest hypercapnia and hypocapnia 
(Published in J Appl Physiol 117:1090-1096, 2014. Used with permission – see Appendix 
C) 
2.1 Introduction 
The responsiveness of the cerebral circulation to altered carbon dioxide (CO2) partial 
pressures has long been recognized (12) and is the basis of one method to assess 
cerebrovascular health (9, 14).  Alterations in vessel diameter have been observed with in 
vitro preparations or craniotomy with changes in inspired CO2 at the level of the smaller 
cerebral arteries including the anterior cerebral artery, the M2 segment of the middle 
cerebral artery (MCA) and the intraparenchymal cerebral arterioles (1, 7). Whether or not 
larger cerebral arteries constrict and/or dilate in conscious humans is important because 
the standard tool for measuring cerebral hemodynamics, transcranial Doppler ultrasound 
(TCD), measures cerebral blood flow velocity (CBFV) which is used as a surrogate for 
cerebral blood flow (CBF). However, the change in CBFV is equivalent to the change in 
CBF only if the diameter of the insonated vessel does not change. This assumption is 
particularly relevant to the M1 segment of the MCA, as it is the cerebral vessel that is 
most often studied using TCD. Early studies used magnetic resonance imaging (MRI) 
and reported that MCA diameter did not change in response to manipulations of end-tidal 
CO2 (ETCO2) (22, 25). Serrador et al. examined MCA diameter during hypercapnia (HC) 
at an ETCO2 of approximately 45 mmHg and during hypocapnia (HO) at 24 mmHg in 6 
subjects and found no change in either condition (22). The voxel dimensions in this case 
were 0.47 x 0.47 x 5.0 mm. Valdueza et al. had 7 subjects hyperventilate to an ETCO2 of 
27 mmHg and no change in MCA diameter was detected with a voxel size of 0.8 x 0.4 x 
3.0 mm (25). Both of these investigations were performed at 1.5 T with limited spatial 
resolution relative to higher field systems currently available. 
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In contrast to MRI data (22, 25), indirect measures suggest that MCA diameter 
does change across levels of ETCO2.  For example, combined measures of the 
hypercapnia-induced flow difference between CBFV in the MCA and the sphenoparietal 
sinus (which drains the MCA) indicated a greater increase on the venous side (26). The 
authors attributed this observation to MCA vasodilation (26).  
Measures of CBFV as an index of CBF are challenged not only by the assumption 
of constant MCA diameter, but also velocity errors. A problem inherent to the Doppler 
signal is overestimation of peak values due to spectral broadening, which has a greater 
impact as the angle of insonation increases (11). Spectral broadening occurs intrinsically 
due to the nature of transmitting and receiving acoustic energy (8) and has been 
documented with other types of Doppler ultrasound systems (11). In addition to TCD, 
MRI-based phase contrast (PC) imaging can estimate CBFV based on the principle that 
applied magnetic gradients induce a phase shift in moving protons that is proportional to 
fluid velocity. Phase contrast imaging has been validated against a flow phantom for 
estimation of total CBF through the basilar artery and internal carotid arteries and has 
been used to estimate MCA CBFV (2, 15, 23). Leung et al. reported that PC-based 
estimates were lower than those measured by TCD with the error attributed to Doppler 
spectral broadening (15). Overall, the agreement between TCD and PC estimates of 
CBFV requires further study. 
The primary purpose of this study was to determine if the MCA constricts during 
HO and/or dilates during HC and to quantify the impact of such changes on CBF. A 
secondary purpose was to compare velocity measures from TCD to velocity measures 
collected with PC MRI over a range of ETCO2 values.  
2.2 Materials and Methods 
In total, nineteen subjects (24 ± 2 years, 8 males) participated in this study. Subjects were 
not on any medications and were non-smokers with no history of cardiovascular disease. 
All subjects gave informed consent and the protocol was approved by the Health 
Sciences Research Ethics Board at Western University. 
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2.2.1 Experimental Protocols 
Subjects participated in two testing sessions including an MRI day and a physiological 
data collection (Lab) day that were matched for time of day. Subjects were asked to 
refrain from alcohol, caffeine and physical activity for 12 hours prior to testing. The 
protocol consisted of 5 minutes of baseline measures followed by 5 minutes of HC or HO 
(assigned randomly) then a 3-4 minute recovery period. The CO2 manipulation that had 
not yet been performed (HC or HO) was then completed for 5 minutes after another 5 
minute baseline. To induce HC the subjects breathed air that consisted of 6% CO2, 21% 
oxygen, and balanced nitrogen.  For HO, participants breathed at a rate of 30 breaths per 
minute guided by a metronome. The protocols were designed to increase ETCO2 by 
approximately 10 mmHg during HC and decrease ETCO2 by approximately 15 mmHg 
during HO. 
2.2.2 Measurements 
2.2.2.1 Lab Session 
Heart rate was acquired from standard ECG. Finger arterial blood pressure (BP) was 
measured continuously and the brachial waveform (Finometer, Finapres Medical Systems 
BV, Amsterdam, The Netherlands) was corrected to brachial sphygmomanometric 
values. End-tidal CO2 (CO2100C analyzer, Biopac, CA, USA) and breathing frequency 
(respiratory strain gauge) were measured continuously. Cerebral blood flow velocity of 
the MCA was measured in a supine position using a 2-MHz pulsed transcranial Doppler 
ultrasound probe (Neurovision system, Multigon Industries, Elmsford, CA, USA). The 
average depth of the ultrasound beam was 5.0 ± 0.4 cm.   
2.2.2.2 MRI Session 
A 3T MRI (Magnetom TIM TRIO, Siemens Medical Solutions, Erlangen, Germany) was 
used for data collection. A 3D time of flight sequence was used to select the location on 
the M1 segment of the right MCA to apply a T2 fast spin echo sequence and a PC 
sequence that were used to determine the vessel cross-sectional area (CSA) and CBFV, 
respectively. Both T2 and PC sequences were applied during baseline conditions (Pre HC 
and Pre HO) and each experimental condition (HC and HO) for 9 subjects (25 ± 2 years, 
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5 males). In each condition, two T2 image acquisitions were performed (approximately 1 
minute per acquisition) followed by one PC acquisition (approximately 2 minutes) 
followed by two more T2 acquisitions. In the MRI session for the remaining subjects 2 to 
5 T2 images were taken at baseline and during HC and HO for assessment of MCA CSA. 
For T2 images, used to calculate MCA CSA, (8 slices, repetition time (TR) = 3000 ms, 
echo time (TE) = 100 ms, flip angle = 120°, voxel dimensions 0.4 x 0.4 x 2.0 mm3), the 
pulse sequence was gated to the peak of the pulse wave from the continuous signal 
derived from an MRI-compatible pulse oximeter (8600FO MRI, Nonin Medical Inc., 
Plymouth, MN, USA) as measured at the right third finger.  
For the PC acquisition, which was used to determine CBFV, (TR = 24.75 ms, TE 
= 6.01 ms, flip angle = 15°, voxel dimensions 0.7 x 0.7 x 3.0 mm3) 25 phases were 
retroactively gated to the signal from the pulse oximeter. The velocity-encoding factor 
(Venc), which is the maximum measurable velocity, was individually determined since 
setting the Venc too low can result in aliasing (18). The Venc for Pre HC and Pre HO 
conditions was, on average, 111 ± 14 m/s, 145 ± 13 m/s for HC, and 98 ± 14 m/s for HO. 
Respiration was collected with a strain gauge around the upper abdomen. 
2.2.3 Data Analysis 
2.2.3.1 Lab Data 
Values of heart rate, BP, breathing frequency, and mean CBFV were averaged for the 5 
minute baseline periods. These measures were averaged every minute during HC and HO 
and the value reported corresponds to when the maximal and minimal CSA 
measurements from the MRI were recorded.  
2.2.3.2 MRI Data 
Figure 2.1 shows a representative baseline T2 image. Using Osirix imaging software 
(Pixmeo, Bernex, Switzerland) the CSA of each MCA image was measured in triplicate 
by two blinded observers. The MCA was assumed to be circular but rather than fitting a 
circle to the vessel we chose to outline the lumen manually point by point for the best fit 
and this was done at each operator’s discretion after training by the same investigator. An 
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intra-class correlation coefficient (ICC) was calculated to examine the agreement 
between the two observers. The ICC between the two observers was 0.92; thus, the 
average CSA between the two observers is reported. The HC and HO CSAs are reported 
as the maximal CSA for HC and the minimal CSA for HO as well as the average of all 
CSAs during HC and HO. The diameter was then determined as the square root of CSA 
divided by π multiplied by 2.  
An index of vascular reactivity was assessed relative to the corresponding 
baseline as the ∆CSA/∆ETCO2 during each of HC and HO. Cerebral blood flow was 
calculated (CSA x CBFV) using TCD CBFV as the basis for CBF calculations unless 
otherwise noted. Percent change (%∆) from baseline was calculated for CBF and CBFV. 
Cerebrovascular reactivity (CVR) for CBF and CBFV was calculated as both absolute 
and relative change (∆CBF/∆ETCO2, ∆CBFV/∆ETCO2, %∆CBF/∆ETCO2, 
%∆CBFV/∆ETCO2).  
Phase contrast data were assessed using cvi42 (Circle Cardiovascular Imaging, 
Calgary, AB, Canada). Phases were quantified into velocities based on the Venc. The 
lumen of the MCA was identified and the mean velocity for each voxel was determined 
over the 25 phases. To coincide with the TCD analysis, a peak velocity for each of the 25 
images was determined from the voxel with the highest velocity within the MCA and 
these values were averaged over the cardiac cycle. The analysis was performed by two 
blinded observers and values were averaged.  The ICC between the two observers was 
1.0 (p<0.001). 
2.2.4 Statistical Analysis 
Data are presented as mean ± standard deviation unless otherwise indicated. 
SigmaStat12.0 was used for statistical analysis. All comparisons were made with a paired 
t-test. Average and maximal/minimum data are reported for HC and HO. The 
maximum/minimum CSA were the main outcome of interest because this represents the 
maximum to which CSA changes may impact TCD estimates of CBFV. Therefore, all 
calculations relating to the change in CSA relate to the maximal CSA during HC and the 
minimum during HO. Bland-Altman analysis was performed to examine the spread of 
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differences between PC and TCD for estimates of CBFV and CVR. The differences 
between the two estimates were plotted against the corresponding means and fixed and/or 
proportional biases were assessed.  A one sample t-test was performed on the difference 
values between the two observers, and between PC and TCD difference values, to test for 
fixed bias since the differences should be equal to zero if no fixed bias exists (3). The 
regression between the differences and corresponding means was plotted and a slope 
different from zero was used to indicate the presence of proportional bias (3). The ICC 
was also calculated to examine the agreement between PC and TCD and a value greater 
than 0.8 was considered to indicate good agreement. 
Cohen’s d was calculated for the change in CSA during HC and HO to provide an 
estimate of the effect size. Additionally, a post hoc power analysis was performed for the 
change in CSA during each of the HO and HC conditions using GPower 3.1 (6) 
specifying two tails, an α-value of 0.05, the sample size, and the effect size of Cohen’s d. 
2.3 Results 
T2 images were collected for 19 subjects and analysis of CSA was performed on images 
from 15 subjects for HO and on 13 subjects for HC for whom image quality provided 
clear MCA edges. Phase contrast images of sufficient quality to determine CBFV were 
obtained in 7 of 9 individuals for both the HC and HO trials and TCD CBFV was 
collected in these same subjects. The average time between the Lab and MRI session was 
53 ± 58 days. This estimate is variable because 13 subjects had their Lab and MRI 
sessions within 29 days of one another while the other 6 had 3 to 4 months between test 
dates due to the reduced availability of the MRI.  
Table 2.1 illustrates the physiologic responses to HC and HO in both the 
laboratory and MRI sessions. End-tidal CO2 increased during HC and decreased during 
HO in each session (p<0.01 for all cases). Breathing rate was not different during HC in 
the MRI or in the Lab session. By design, breathing rate was elevated compared to 
baseline during HO in each session (p<0.001). Additionally, heart rate increased during 
both HC and HO in the MRI and Lab sessions (p<0.05 for all cases). Blood pressure was 
measured only in the Lab session and during HC, SBP and MAP increased above 
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baseline (p<0.05 for both cases) while DBP remained unchanged. During HO, SBP 
increased above baseline (p<0.01) while MAP and DBP remained unchanged.  
During HC, CSA of the MCA increased from 5.6 ± 0.8 at baseline to a maximal 
CSA of 6.5 ± 1.0 mm2 (p<0.001; Figure 2.2A) and an average CSA of 6.3 ± 0.9 mm2 
(p<0.001). During HO, the CSA decreased from 5.8 ± 0.9 at baseline to a minimum of 
5.3 ± 0.9 mm2 (p<0.001; Figure 2.2B) and an average CSA of 5.5 ± 0.9 mm2 (p=0.01). 
For HC, Cohen’s d was 0.94 and the achieved power was 0.87. For HO, Cohen’s d was 
0.50 and achieved power was 0.44.  Figure 2.2 illustrates the individual patterns of 
response showing a homogeneous dilatory response for all subjects during HC and 
heterogeneous vasoconstriction during HO where 6 participants showed less than a 5% 
change in MCA CSA. Figure 2.3 shows the mean and individual data for the relationship 
between ETCO2 and CSA.  The average increase during HC was 0.11 ± 0.07 mm
2/mmHg 
while the average decrease during HO was 0.04 ± 0.03 mm2/mmHg.  
Both PC and TCD methods produced similar significant changes in CBFV during 
both HC and HO stimuli. Overall, there was a strong linear association between TCD and 
PC estimates of CBFV (r=0.71, p<0.001; Figure 2.4B). The limits of agreement with 
Bland-Altman analysis were at -27 and 20 on the y-axis (Figure 2.4A) and 1 value fell 
outside this range at approximately y=23. Bland-Altman analysis revealed no significant 
fixed (mean difference -3.56 cm/s; p=0.13) or proportional biases (r=0.01; p=0.98). 
However, the spread of the differences between PC and TCD produced limits of 
agreement with a wide range. The ICC for CBFV was 0.83 (p<0.001). 
There were no differences in CVR between CBFV estimates obtained by TCD 
and PC for HC or HO (TCD: 2.42 ± 3.98 cm/s/mmHg; PC: 2.87 ± 1.63 cm/s/mmHg, for 
HC p=0.33 and TCD: -1.67 ± 1.37 cm/s/mmHg; PC: -0.92 ± 1.17 cm/s/mmHg, for HO 
p=0.14). There was a strong linear association between TCD and PC CVR (r=0.81, 
p<0.001; Figure 2.5B). Bland-Altman analysis for CVR (Figure 2.5A) revealed one point 
that fell outside the limits of agreement of -3.6 and 4.8. No fixed bias (mean difference 
0.6 cm/s/mmHg; p=0.10) was observed; however, the slope of the regression line was 
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different from zero (r=0.57; p=0.032), indicating proportional bias was present. The ICC 
for CVR was 0.86 (p<0.001).   
Cerebral blood flow, calculated from TCD CBFV and MCA CSA, increased from 
baseline during HC and decreased during HO (p<0.01 for each; Figure 2.6A). The %∆ 
was greater for CBF than for CBFV during HC and HO (p<0.001 for each comparison; 
Figure 2.6B). There was also a significant change from baseline during HC (from 219 ± 
38 to 333 ± 68 ml/min; p=0.001) and HO (from 211 ± 34 to 156 ± 13 ml/min; p=0.007) 
when CBF was calculated from PC CBFV and MCA CSA. Cerebrovascular reactivity 
calculated from CBF was 19 ± 23 ml/min/mmHg for HC and -8 ± 6 ml/min/mmHg for 
HO. Comparing %∆CBFV CVR to %∆CBF CVR revealed that the reactivity to HC and 
HO was greater for %∆CBF CVR than %∆CBFV CVR (p<0.05 for both cases; Figure 
2.7).  
 
 
 
 
 
 
 
 
 
 
 
43 
 
Table 2.1: Physiological results during HC and HO in the lab and MRI. 
 Pre HC HC Pre HO HO 
MRI     
End tidal carbon dioxide (mmHg) 37 ± 3 46 ± 5* 36 ± 4 23 ± 3† 
Breathing rate (breaths per minute) 13 ± 3 15 ±3 13 ± 4 28 ± 1† 
Heart rate (beats per minute) 63 ± 6 67 ± 7* 67 ± 11  76 ± 12† 
Lab     
End tidal carbon dioxide (mmHg) 39 ± 3 49 ± 5* 36 ± 4 25 ± 9† 
Breathing rate (breaths per minute) 14 ± 2 16 ± 3 14 ± 3 29 ± 1† 
Heart rate (beats per minute) 61 ± 9 65 ± 6* 64 ± 9 69 ± 7† 
Systolic blood pressure (mmHg) 107 ± 11 112 ± 13* 110 ± 8 114 ± 9† 
Diastolic blood pressure (mmHg) 69 ± 8 70 ± 10 69 ± 8 70 ± 8 
Mean arterial pressure (mmHg) 82 ± 9 86 ± 10* 84 ± 7 85 ± 7 
44 
 
Values are means ± SD. *p<0.05 for Pre HC versus HC. †p<0.05 for Pre HO versus HO. MRI: HC n=13, HO n=15. Lab: HC and HO 
n=7. HC = hypercapnia; HO = hypocapnia.   
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Table 2.2: CBFV during HC and HO obtained from TCD and PC MRI. 
 Pre HC HC Pre HO HO 
TCD CBFV (cm/s) 68 ± 9 85 ± 15* 69 ± 8 55 ± 16† 
PC CBFV (cm/s) 64 ± 10 85 ± 15* 61 ± 8 51 ± 8† 
Values are means ± SD. *p<0.05 for Pre HC versus HC. †p<0.05 for Pre HO versus HO. TCD and PC: HC n=7 and HO n=7. CBFV = 
cerebral blood flow velocity; HC = hypercapnia; HO = hypocapnia; PC = phase contrast; TCD = transcranial Doppler ultrasound. 
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Figure 2.1: Sagittal T2 baseline image through the right middle cerebral artery of a 
representative subject. 
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Figure 2.2: Individual and mean changes in the CSA of the middle cerebral artery. A: 
HC (n=13). B: HO (n=15). CSA = cross-sectional area; HC = hypercapnia; HO = 
hypocapnia. 
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Figure 2.3: Relationship between the change in ETCO2 and the change in middle 
cerebral artery CSA from HO to HC. Filled squares represent mean data with standard 
deviation bars and unfilled squares show individual data (n=19; n=9 with data points for 
HO and HC, n=6 for HO alone, and n=4 for HC alone). CSA = cross-sectional area; 
ETCO2 = end-tidal carbon dioxide; HC = hypercapnia; HO = hypocapnia. 
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Figure 2.4: Bland-Altman and scatter plots comparing TCD and PC CBFV over the 
range of end-tidal carbon dioxide values. Pre HC, HC, Pre HO and HO are represented 
for 7 subjects for a total of 28 data points. A: Bland-Altman plot of CBFV. B: Scatter plot 
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with the regression line (solid line) and 95% confidence intervals (dashed lines) for 
CBFV. CBFV = cerebral blood flow velocity; PC = phase contrast; TCD = transcranial 
Doppler ultrasound. 
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Figure 2.5: Bland-Altman and scatter plots comparing TCD and PC CVR over the range 
of end-tidal carbon dioxide values. The change from Pre HC to HC and Pre HO to HO 
are represented for 7 subjects for a total of 14 data points. A: Bland-Altman plot of CVR. 
B: Scatter plot with the regression line (solid line) and 95% confidence intervals (dashed 
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lines) for CVR. CVR= cerebrovascular reactivity; PC = phase contrast; TCD = 
transcranial Doppler ultrasound. 
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Figure 2.6: A: CBF during HC and HO calculated by multiplying the cross-sectional area 
of the MCA by TCD CBFV. B: Percent change in CBFV and CBF during HC and 
HO.*p<0.05. CBF = cerebral blood flow; CBFV = cerebral blood flow velocity; HC = 
hypercapnia; HO = hypocapnia; MCA = middle cerebral artery; TCD = transcranial 
Doppler ultrasound. n=7 for all conditions. 
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Figure 2.7: Cerebrovascular reactivity expressed as percent change of CBFV and CBF 
divided by the change in end tidal carbon dioxide during HC and HO.*p<0.05. CBF = 
cerebral blood flow; CBFV = cerebral blood flow velocity; CVR = cerebrovascular 
reactivity; HC = hypercapnia; HO = hypocapnia; MCA = middle cerebral artery; TCD = 
transcranial Doppler ultrasound. n=7 for all conditions. 
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2.4 Discussion 
This study was the first to show that MCA CSA increases by 16 ± 7% and decreases by 8 
± 6% during HC and HO, respectively. Thus, using CBFV as an estimate of flow 
underestimated true flow changes in the MCA. Cerebrovascular reactivity was also lower 
when using CBFV compared to CBF. Additionally, there was some variability between 
TCD and PC estimates of CBFV during both HC and HO conditions which was evident 
by the wide limits of agreement produced from Bland Altman analysis despite the strong 
ICC value.  
Overall, MCA diameters calculated from measures of CSA in the current study 
(2.66 ± 0.21 to 2.87 ± 0.21 mm for HC and 2.69 ± 0.20 to 2.59 ± 0.21 with HO) are 
comparable to values of 2.23 mm (24) to 3.4 mm (10, 21, 22, 25, 28) from other studies 
that have employed MRI. In the current analysis, the percent change in diameter with HC 
was 8 ± 3 % over an average change in ETCO2 of 9 ± 4 mmHg whereas diameter 
decreased 4 ± 4 % during an ETCO2 decrease of 13 ± 5 mmHg. Willie et al. (2012) 
reported a change in the diameter of the internal carotid artery of approximately 20% 
over a PaCO2 range of 50 mmHg (27). Thus, the current data produced a rate of diameter 
change (approximately 0.4%/mmHg) over a physiologically-relevant range of ETCO2 
that is consistent with that of the internal carotid artery (approximately 0.6%/mmHg) 
observed over a much wider range of ETCO2.   
Previously, MCA diameter was observed not to change across a similar range of 
ETCO2 examined in the current study (22, 25). However, Serrador et al. (2000) used 1.5 
T MRI with a voxel size of 0.47 x 0.47 x 5.00 mm giving a total voxel volume of 1.11 
mm3 (22). In the current study, the resolution of the 3T system was greater with a voxel 
size of 0.4 x 0.4 x 2.0 mm for a voxel volume of 0.32 mm3. The voxel volume affects not 
only the resolution but also the impact of partial volume effects. In particular, the smaller 
voxel volume of the 3T system used here will reduce the presence of two or more types 
of tissue in one voxel where signal from one would “water down” signal from the second. 
With the larger voxel volume in the previous study partial volume effects may have 
minimized any detectable change (22). In addition, a higher signal-to-noise ratio was 
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achieved with the 32 channel head coil and the signal-to-noise ratio is inherently two 
times greater at 3 T compared to 1.5 T (4). Some variability in MCA CSA was observed 
across subjects in the current study, especially during HO. The observation of a greater 
dilatory response to HC versus constrictor response to HO is consistent with previous 
observations of the internal carotid artery (27). We observed high between-subject 
variability in the constrictor response to HO which suggests either varying sensitivity to 
CO2 or that the MCA exists in a constricted state at baseline. Giller et al. (1993) also 
observed variability in the response to HO upon direct observation of the MCA during 
craniotomy (7). We speculate that the brain could be protected from inappropriate 
vasoconstriction which could lead to damaging ischemia, particularly if it involves the 
major arteries at the base of the brain. In this context, baseline flow may be the regulated 
variable in the brain as opposed to the PaCO2.  
In the current study no significant biases were observed when comparing TCD 
and PC estimates of CBFV. Additionally, the ICC was strong indicating that variation 
between the two methods in the same subject was minimal compared to variation 
between subjects. However, the variability in the differences between the two methods 
produced quite a spread of data, resulting in wide limits of agreement. Leung et al. 
observed proportional bias with less agreement between the two methods at high levels of 
CBFV during HC (15). However, in this study, proportional bias was observed only with 
CVR due to one data point where CVR was highest. This indicates that TCD and PC may 
not provide similar estimates of CBFV in individuals who express a large CVR response 
to HC. Leung et al. suggested that one way to reduce this variability between the two 
methods may be to compare the mean CBFV signal instead of the peak signal which may 
reduce partial volume effects (15).   
 The increase in MCA CSA with HC may be influenced by the concurrent rise in 
BP. In this study, mean arterial pressure increased during HC by approximately 5 ± 3%. 
Under conditions of normal ETCO2 a change in BP should have minimal effect on CBF 
due to intact cerebral autoregulation. However, under hypercapnic conditions dynamic 
cerebral autoregulation is impaired (19). Thus, it is possible that the cerebral circulation 
may respond passively to small BP changes leading to an effect on the CSA of the MCA 
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during HC. Indeed, pharmacological studies indicate that larger cerebral vessels, such as 
the internal carotid artery, can change diameter passively during changes in BP (16). 
Based on these earlier data (16), the change in diameter in internal carotid artery diameter 
that could be expected with our change in BP is approximately 3% (16) which is less than 
the 8% diameter change observed. However, the study of Liu et al. was performed under 
conditions of normocapnia so it is unclear how HC may affect these results (16).  
This study is limited by the fact that MCA CSA and TCD measurements were 
collected on different days that were, on average, 53 days apart. We attempted to 
decrease day to day variability by performing data collection at the same time of day in 
the separate sessions. Despite this limitation, studies suggest that TCD and PC estimates 
of CBFV are reproducible over a week in the case of TCD and over 72 days for PC (5, 
23). These studies are limited by the fact that they examined repeatability under 
conditions of normocapnia. Few studies that have assessed the reproducibility of 
cerebrovascular reactivity to carbon dioxide have produced variable findings. McDonnell 
et al. found the ICC between two estimates of TCD-based CBFV change during HC 
performed a week apart to be fairly strong (ICC=0.73) in one rater who had more recently 
been trained, but much weaker in the other rater (ICC=0.08) (17). Additionally, BP 
measurements were not taken during the MRI session.   
Another limitation of the current study was that PaCO2 was not measured. 
Previous studies indicate that ETCO2 overestimates PaCO2 during HC but not HO (20, 
27). Regardless, ETCO2 was used in all cases so any overestimation was comparable 
between TCD and PC. 
Lastly, it must be noted that in a minimal number of T2 images the vessel borders 
were unclear and as result were not analyzed. Respiratory-induced motion artifacts can be 
problematic and were a concern for this study. All images used in this study were 
carefully monitored for significant motion problems like blurring or ghosting. It is 
unlikely that the image quality could be significantly improved through the use of 
respiratory gating for the following reasons:  (1) the significant increase in scan time 
during the T2 turbo spin echo sequence used in this study could potentially introduce 
58 
 
patient movement artifacts other than respiration itself, and (2) the potentially large 
variation between TR periods in this acquisition would significantly alter the spin history 
and introduce other unwanted magnitude and phase variances and therefore image 
artifacts.  
 In summary, the present data support the conclusion that the CSA of the MCA 
changes in response to changes in ETCO2. The response was more homogeneous across 
participants during HC than HO. These data contribute to emerging evidence that 
alterations in CBF due to manipulations of the arterial partial pressure of CO2 and/or the 
arterial partial pressure of oxygen are not solely due to changes in the smaller arterioles 
(27, 28). Therefore, caution must be applied when using CBFV as a surrogate for CBF 
during conditions that manipulate concentrations of arterial gases.  
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Chapter 3  
3 Heterogeneous patterns of vasoreactivity in the middle 
cerebral and internal carotid arteries 
(Published in Am J Physiol Heart Circ Physiol. 2015 Feb 27:ajpheart.00761.2014. doi: 
10.1152/ajpheart.00761.2014. [Epub ahead of print]. Used with permission – see 
Appendix C) 
3.1 Introduction 
It is well known that the cerebral vessels demonstrate high sensitivity to levels of carbon 
dioxide (CO2) (7) but the exact mechanisms of this reactivity have yet to be elucidated (1, 
13, 20). The relative change in flow or flow velocity to a given change in end tidal CO2 
(ETCO2) is a standard  measurement known as cerebrovascular reactivity (CVR) that 
reflects the health of the cerebrovascular system (11) and the risk for a future ischemic 
event (15).  The relative contributions of subcortical and intraparenchymal vessels to 
estimates of CVR remain unknown and the reactivity is generally attributed to the pial or 
intraparenchymal vessels. Yet, estimates based on the fall in pressure from the aorta 
indicate that the large subcortical or cerebral arteries contribute as much as 50 to 60% to 
cerebrovascular resistance (5). Thus, understanding their reactivity to changes in CO2 has 
important implications for determining cerebrovascular health. 
The contribution of the conduit vessels to CVR remains unclear in intact humans 
due to lack of access to direct in vivo assessment of these vessels. This limitation has led 
to reliance on transcranial Doppler ultrasound (TCD) to assess cerebral vasomotor 
control, a method that is applied easily and provides excellent temporal resolution of 
cerebral blood flow velocity (CBFV). Although the total power of the Doppler signal has 
been used to account for possible changes in middle cerebral artery (MCA) cross-
sectional area (CSA) (12), TCD cannot quantify cerebral blood flow (CBF) because the 
CSA of the insonated vessel cannot be visualized directly. Thus, CBFV is accepted as a 
suitable analog of CBF. This supposition is supported by earlier magnetic resonance 
imaging (MRI) studies in which changes in MCA diameter were not observed during 
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hypocapnia (HO: hyperventilation to 24 mmHg (14) and 27 mmHg (18)) or hypercapnia 
(HC: ETCO2 increased to 45 mmHg (14)).  
Recently, we used 3T MRI and a 32 channel head-coil to enhance resolution and 
observed a statistically significant change in MCA diameter of 8 ± 3% during HC 
(ETCO2 increased 9 mmHg above baseline) and a decrease in diameter of 4 ± 4% during 
HO (ETCO2 decreased by 13 mmHg) (4). Thus, concurrent measures of  CBFV alone 
using phase contrast imaging or TCD, underestimated the true CBF by as much as 20% 
(4). These observations were based on assessment of the maximal CSA during five 
minute periods of HC and the minimal CSA during hyperventilatory HO. These MCA 
diameter changes were replicated at 7T during HC by an independent group who reported 
a 7 ± 3% diameter change when ETCO2 was kept constant at 15 mmHg above each 
subject’s baseline (19). The time course of dilation and the contribution of the MCA to 
changes in CVR remain fundamental to gaining greater understanding of the 
contributions of these vessels versus downstream segments of the vascular tree to 
cerebrovascular control.  
 The internal carotid artery (ICA) diameter changes by approximately 20% over a 
range of partial pressures of CO2 (PaCO2) from 15 to 65 mmHg while the partial pressure 
of oxygen (PO2) was clamped (21). However, the timing of this response is unknown as 
the diameter measures were made after 12 to 15 minutes of CO2 stimulus. Since the ICA 
can be insonated by the more cost-effective and accessible method of ultrasound it would 
be useful to determine if the changes in the ICA CSA during HC and HO mimic the 
changes in the MCA.  
The purposes of this study were to determine the time course of the change in 
CSA and flow of the MCA and ICA over 5 minutes of HC and HO in healthy individuals 
and to study the contributions of MCA CSA data to the estimation of CVR values. We 
also estimated wall shear stress (WSS) in order to quantify how flow-mediated effects 
may contribute to the vascular responses.  
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3.2 Materials and Methods 
Fourteen subjects (23 ± 3 years, 7 females) gave informed consent to participate in this 
study that was approved by the Health Sciences Research Ethics Board at Western 
University and performed in accordance with the Declaration of Helsinki. Subjects were 
non-smokers, were not on any medications, and had no history of cardiovascular disease.  
3.2.1 Experimental Protocols 
Subjects participated in two test days: 1) a Lab day where TCD of the MCA and duplex 
imaging of the ICA were performed and 2) a separate MRI day. The Lab and MRI days 
were matched for time of day. Subjects were asked to refrain from alcohol, caffeine and 
physical activity for 12 hours prior to testing. The protocol on each test day consisted of 5 
minutes of baseline measures (Pre HC and Pre HO) followed by 5 minutes of 
hypercapnia (HC) or hypocapnia (HO) (the order of which was counterbalanced across 
participants) then a 3 to 4 minute recovery period to allow ETCO2 levels to return to 
normal. The PO2 was not clamped during the ETCO2 manipulations. Another 5 minute 
baseline was then performed followed by the ETCO2 manipulation that had yet to be 
performed. For HC, subjects breathed air composed of 6% CO2, 21% oxygen, and 72% 
nitrogen. Hypocapnia was induced by hyperventilation at 30 breaths per minute guided 
by a metronome. Previous use of these protocols in our lab suggested that ETCO2 levels 
remain fairly constant (within ~1-2 mmHg) over the 5 minutes during each manipulation 
(23).  
3.2.2 Measurements 
3.2.2.1 Lab Session 
Heart rate was acquired from standard ECG. Finger arterial blood pressure (BP) was 
measured continuously (Finometer, Finapres Medical Systems BV, Amsterdam, The 
Netherlands). The brachial BP waveform was corrected to brachial sphygmomanometric 
values. Breathing frequency and ETCO2 were monitored continuously with a respiratory 
strain gauge and a gas analyzer (ML206, ADInstruments, Colorado Springs, CO, USA) 
respectively. Right middle cerebral artery velocity (MCAv) was measured in a supine 
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position (2 MHz pulsed wave TCD probe; Neurovision, Multigon Industries, Elmsford, 
CA, USA). The average depth of insonation was 4.8 ± 0.3 cm.  
Duplex ultrasound imaging was used to record the right ICA flow velocity (ICAv) 
(Doppler ultrasound, 4.7 MHz probe) continuously while a longitudinal image of the 
vessel was taken every minute during baseline and each protocol (10 MHz probe; Vivid 7 
system, GE Healthcare Canada, Mississauga, ON, Canada).  The ICA recording site was 
at least 1 cm superior to the carotid sinus. Velocity waveforms were processed to produce 
an analog signal of the instantaneous weighted mean flow velocity. The 2D echo 
ultrasound images were stored for analysis with EchoPAC software (GE Healthcare 
Canada, Mississauga, ON, Canada). 
3.2.2.2 MRI Session 
A 3T MRI (Magnetom Prisma, Siemens Medical Solutions, Erlangen, Germany) was 
used to image the MCA. A 3D time of flight pulse sequence was used to identify the M1 
segment location for application of a T2 fast spin echo sequence (8 slices, repetition time 
= 3000 ms, echo time = 96 ms, flip angle = 120°, voxel dimensions = 0.4 x 0.4 x 2.0 
mm3) for image acquisition. Collection of an image took approximately one minute and 
was gated to the peak of the pulse wave at the finger derived from an MRI-compatible 
pulse oximeter (8600FO MRI, Nonin Medical Inc., Plymouth, MN, USA) as measured at 
the right third finger. Respiration was monitored with a strain gauge around the upper 
abdomen and ETCO2 data were collected as described during the Lab session. 
3.2.3 Data Analysis 
Three systolic and three diastolic diameters were measured for each ICA image by a 
blinded observer and an average of the three was taken. The accuracy of measurement 
was confirmed by a second blinded observer using images from four participants across 
the range of image quality (a total of 92 images) producing an intraclass correlation 
coefficient (ICC) of 0.89 (p<0.001). A mean diameter was then calculated as: mean 
diameter (mm) = (2/3*diastolic diameter (mm)) + (1/3*systolic diameter (mm)). Internal 
carotid artery flow (QICA) was determined as: QICA (ml/min) = ICAv (cm/s)*[π*(mean 
diameter (cm)/2)2]*60 (s/min).  
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From the sagittal images, the MCA CSA was measured manually in triplicate by 
each of two blinded observers using Osirix imaging software (Pixmeo, Bernex, 
Switzerland) (ICC of 0.96; p<0.001) and the data from both observers were averaged and 
reported. An estimate of blood flow in the MCA (QMCA) was determined as: QMCA 
(ml/min) = MCAv (cm/s)*CSA (cm2)*60 (s/min). The reproducibility of MCA flow 
velocity responses to HC and HO has been established in our hands under laboratory and 
MRI conditions, albeit with separate modalities (i.e., TCD and phase contrast imaging) 
(4). Therefore, QMCA data were based on MCAv and CSA data that were collected on 
separate days. When reported, the MCA diameter was calculated from the measured CSA 
value. The percent change (%∆) in CSA between baseline and HC or HO time points was 
also calculated for the ICA and the MCA.  
Flow indices for each vessel are reported both as absolute values and as %∆ to 
account for differences in baseline flow. Cerebrovascular conductance (CVC) was 
calculated for the ICA and the MCA as the quotient of flow and mean arterial pressure 
(MAP). CVR was calculated for both arteries as the %∆ in flow from baseline per mmHg 
change in ETCO2 at each minute of the 5 minute period during HC and HO. Wall shear 
stress was calculated for the MCA and the ICA at baseline and each minute of HC and 
HO as: WSS (τ, dyn/cm2) = 4*η*Q/r3*π, where η is the blood viscosity (0.009 Poise), Q 
is flow (ml/min) and r is the radius of the inside of the artery (cm) (3).  
All variables were similar in the baseline periods of the Lab and MRI sessions so 
an average of this five minute period is reported for heart rate, BP, breathing frequency, 
ETCO2, MCAv, ICAv, QICA, QMCA, CVC, CVR and WSS indices. The values during HC 
and HO are reported for each minute over the 5 minute period.  
3.2.4 Statistical Analysis 
The effect of HC or HO on the time course of MCA and ICA changes in CSA, with the 
corresponding ETCO2, heart rate and respiration outcomes, were characterized first using 
one-way repeated measures ANOVAs (main effect of time) (SigmaStat 12.0, Systat 
Software, San Jose, CA, USA). Subsequently, the effects of HC and HO on MCA and 
ICA over time were assessed using a general linear mixed ANOVA model (main effects 
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of artery). Additionally, comparisons between Lab values of ETCO2, heart rate, and 
respiration to MRI values over time were performed with general linear mixed ANOVA 
(main effect of experimental session). The effect of HC and HO on the index of WSS was 
examined using one-way repeated measures ANOVA. The probability level for statistical 
significance was p<0.05 and significant main effects or interactions were assessed using 
Tukey’s post hoc test. A post-hoc power analysis was performed with G*Power 3.1 (31) 
specifying two tails, an α-value of 0.05, the sample size and the effect size (Cohen’s d). 
3.3 Results 
Clear MCA images and complete data for MCAv and QICA were obtained from 11 
participants (23 ± 3 years, 5 females) during HC at baseline and sample sizes at each of 
the 5 time points were: 9, 10, 9, 9, and 8, respectively. The Pre HO sample size was 9 (23 
± 3 years, 4 females) and the sample sizes at each of the 5 time points were 8, 9, 8, 9, and 
5, respectively.  
During HC there was a main effect of time for all BP variables, heart rate, 
respiration rate, ETCO2, and CVC but there was no effect of artery (Table 3.1). Thus, the 
experimental stimuli and conditions were replicated for each of the two protocols within 
the same session that studied the MCA and the ICA responses. When the MCA, ICA and 
MRI protocols were compared there was a trend for a main effect of experimental session 
for respiration rate (p=0.06) and no differences for ETCO2 or heart rate.  
Compared with baseline, a main effect of time was observed during HO for heart 
rate, respiration rate, and ETCO2 but not for BP variables and there was no effect of 
artery for any of these variables when the ICA and MCA protocols were compared (Table 
3.2). However, main effects of time and artery were observed for CVC where constriction 
of the downstream vascular bed was observed in both vessels but overall levels were 
greater in the ICA. During HO, there was a main effect of experimental session when 
comparing the MCA, ICA and MRI protocols for ETCO2 (p=0.05) and no differences in 
heart rate or respiration rate.  
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Table 3.3 shows the changes in heart rate and respiration rate during HC and HO 
in the MRI session. In the MRI during HC, heart rate was increased compared to baseline 
at minutes 2 to 5 of HC (p<0.05). Additionally, respiration rate was increased at minutes 
4 and 5 compared to minute 1 of HC (p=0.04 for each). Compared to baseline, heart rate 
was elevated at all time points of HO (p<0.05) except minute 5. By design, breathing rate 
was elevated at all time points in HO (p<0.001).  
Figure 3.1A shows the time course of the MCA CSA response to HC. The MCA 
CSA increased progressively above baseline over the five minutes of HC (p<0.05). 
Compared to baseline (5.8 ± 1.1 mm2), the largest MCA CSA (6.8 ± 1.3 mm2; +14 ± 8%) 
occurred at four minutes of HC. A main effect for time (p=0.05) was observed for the 
ICA CSA response to HC (Figure 3.1B) but no pairwise comparisons reached 
significance despite ETCO2 levels that were greater than baseline at each time point 
(p<0.001). Main effects of time (p<0.001) and artery (p<0.001) were observed for 
%∆ICA and %∆MCA CSA (Figure 3.1C). In terms of QICA and QMCA a main effect of 
time (p<0.001) and a trend for a difference between arteries (p=0.07) were observed 
during HC (Figure 3.1D).The %∆QMCA and %∆QICA increased similarly with time 
(p<0.001) in each artery (Figure 3.1E).  
Figure 3.2A illustrates the change in MCA CSA during HO. Compared to 
baseline, the MCA CSA was reduced from baseline (5.9 ± 0.8 mm2) only at minutes four 
(p=0.01 versus baseline and p=0.003 versus HO min 1) and five (5.1 ± 0.5 mm2 at HO5; 
6 ± 6%; p=0.03 versus baseline and p=0.008 versus HO min 1). The ICA CSA was not 
different from baseline at any time point during HO despite significant and rapid 
reductions in ETCO2 (Figure 3.2B). A main effect of time (p=0.02) was observed for 
%ΔCSA of the ICA and MCA during HO (Figure 3.2C). Main effects of time (p<0.001) 
and artery (p=0.006) were observed for absolute QICA and QMCA values during HO 
(Figure 3.2D) but not for %∆ of either value (Figure 3.2E).  
During HC, a time x method interaction was observed such that the %∆MCAv 
was less than %∆QMCA and this effect was present after three minutes of HC (p<0.02; 
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Figure 3.3A). During HO, a main effect for time (p<0.001) was observed indicating 
similar relative reductions in both MCAv and QMCA.  
Compared with baseline, MCA WSS was elevated at all HC time points (p<0.01), 
and time points 2, 4, and 5 were greater than 1 (p<0.03; Table 3.4). Compared with 
baseline, MCA WSS was reduced at all HO time points (p<0.05). In the ICA, wall shear 
stress increased progressively during HC with time points 2 to 5 minutes being different 
from baseline (p<0.001) and time points 4 and 5 minutes being greater than the first 
minute of HC (p<0.05). During HO the ICA WSS was reduced compared to baseline at 
all time points except minute five (p<0.05).   
The contributions of changes in CSA to the overall CVR outcome was examined 
by using MCAv and QMCA to calculate CVR. After five minutes, CVR was 3.13 ± 1.55 
%/mmHg when MCAv was used and 4.88 ± 2.46 %/mmHg using QMCA (Figure 3.4A). 
This is a difference of 58 ± 25% in CVR. Using ICAv and QICA to calculate CVR during 
HC resulted in very similar estimates to those calculated from QMCA after five minutes, 
although the pattern of response appears to be different (using ICAv: 4.56 ± 2.02 
%/mmHg and using QICA: 4.70 ± 1.93 %/mmHg at minute five; Figure 3.4A). 
Hypocapnia elicited a similar CVR value at five minutes when it was calculated using 
ICAv, QICA and MCAv despite a different response pattern between MCAv and estimates 
based on ICAv. Additionally, CVR calculated using QMCA was smaller than any of the 
other estimates indicating that failure to account for MCA CSA changes leads to an 
underestimation of CVR to HO (Figure 3.4B).  
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Table 3.1: Physiological responses to hypercapnia in the ICA and the MCA over time. 
Time 
Sample 
 Pre 
(11) 
1 
(9) 
2 
(10) 
3 
(9) 
4 
(9) 
5 
(8) 
P-value 
Time Artery 
SBP  
(mmHg) 
ICA 112 ± 10 114 ± 12 115 ± 11 116 ± 13 116 ± 12 118 ± 14 <0.001 0.97 
MCA 111 ± 12 114 ± 12 116 ± 13 117 ± 14 116 ± 13 118 ± 13 
DBP 
(mmHg) 
ICA 68 ± 10 66 ± 6 67 ± 6 67 ± 8 68 ± 9 70 ± 9 0.021 0.94 
MCA 66 ± 8 66 ± 8 67 ± 8 67 ± 9 68 ± 9 70 ± 9 
MAP 
(mmHg) 
ICA 82 ± 8 83 ± 7 84 ± 6 85 ± 8 86 ± 9 87 ± 9 <0.001 0.94 
MCA 82 ± 8 83 ± 9 84 ± 8 84 ±9 86 ± 9 86 ± 9 
HR 
(bpm) 
ICA 60 ± 7 63 ± 6 66 ± 8 64 ± 11 66 ± 11 62 ± 9 <0.001 0.48 
MCA 62 ± 11 67 ± 11 67 ± 9 68 ± 10 70 ± 11 66 ± 8 
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Resp 
(breaths/min) 
ICA 15 ± 3 15 ± 3 15 ± 2 16 ± 2 16 ± 2 16 ± 1 <0.001 0.50 
MCA 14 ± 3 15 ± 2 15 ± 2 15 ± 3 15 ± 2 16 ± 2 
ETCO2 
(mmHg) 
ICA 39 ± 5 48 ± 3 49 ± 4 49 ± 5 49 ± 4 49 ± 5 <0.001 0.55 
MCA 40 ± 4 49 ± 4 50 ± 4 51 ± 5 51 ± 5 50 ± 5 
CVC 
(ml/min/ 
mmHg) 
ICA 4.0 ± 1.2 4.3 ± 1.3 4.7 ± 1.3 5.0 ± 1.6 5.5 ± 2.2 4.9 ± 1.4 <0.001 0.12 
MCA 3.0 ± 1.0 3.8 ± 1.4 4.0 ± 1.2 4.4 ± 1.3 4.4 ± 1.3 3.9 ± 1.3 
Values are mean ± standard deviation. Sample sizes are shown in brackets. No time x artery interactions were present. CVC = 
cerebrovascular conductance; DBP = diastolic blood pressure; ETCO2 = end tidal carbon dioxide; HR = heart rate; ICA = internal 
carotid artery; MAP = mean arterial pressure; MCA = middle cerebral artery; Resp = respiration rate; SBP = systolic blood pressure. 
Values for ICA and MCA were obtained during separate trials of the same session, acquired in varied order. 
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Table 3.2: Physiological responses to hypocapnia in the ICA and the MCA over time. 
Time 
Sample 
 Pre 
(9) 
1 
(8) 
2 
(9) 
3 
(8) 
4 
(9) 
5 
(5) 
P-value 
Time Artery 
SBP 
(mmHg) 
ICA 119 ± 9 120 ± 12 121 ± 12 119 ± 15 118 ± 12 120 ± 13 0.35 0.70 
MCA 118 ± 12 116 ± 13  118 ± 12 116 ± 11 117 ± 13 117 ± 4 
DBP 
(mmHg) 
ICA 69 ± 10 69 ± 12 71 ± 11 70 ± 12 69 ± 11  71 ± 11 0.19 0.85 
MCA 69 ± 9 67 ± 9 68 ± 10 68 ± 9 69 ± 9 70 ± 8 
MAP 
(mmHg) 
ICA 87 ± 9  87 ± 11 89 ± 11 88 ± 13 87 ± 11 88 ± 11 0.14 0.70 
MCA 86 ± 9 84 ± 10 85 ± 10 84 ± 9 85 ± 10 87 ± 4 
HR 
(bpm) 
ICA 60 ± 12 66 ± 10 62 ± 12 66 ± 12 65 ± 12 64 ± 11 <0.001 0.95 
MCA 60 ± 11 65 ± 13 65 ± 14 66 ± 15 65 ± 13 62 ± 9 
Resp 
(breaths/min) 
ICA 15 ± 3 29 ± 1 28 ± 3 29 ± 2 29 ± 2 28 ± 5 <0.001 0.93 
MCA 14 ± 3  29 ± 2 29 ± 2 30 ± 1 28 ± 2 28 ± 2 
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ETCO2 
(mmHg) 
ICA 39 ± 3 31 ± 4 30 ± 3 29 ± 4 29 ± 3 28 ± 2 <0.001 0.47 
MCA 39 ± 5 30 ± 4 29 ± 5 28 ± 5 27 ± 5 25 ± 4 
CVC (ml/min/ 
mmHg) 
ICA 3.4 ± 0.7 2.8 ± 0.3 2.5 ± 0.3 2.7 ± 0.3 2.8 ± 0.7 2.5 ± 0.4 <0.001 0.023 
MCA 2.7 ± 0.7 2.4 ± 0.7 2.2 ± 0.7 2.2 ± 0.5 2.0 ± 0.6 2.0 ± 0.7 
Values are mean ± standard deviation. Sample sizes are shown in brackets. No time x artery interactions were present. CVC = 
cerebrovascular conductance; DBP = diastolic blood pressure; ETCO2 = end tidal carbon dioxide; HR = heart rate; ICA = internal 
carotid artery; MAP = mean arterial pressure; MCA = middle cerebral artery; Resp = respiration rate; SBP = systolic blood pressure. 
Values for ICA and MCA were obtained during separate trials of the same session, acquired in varied order. 
 
 
 
 
 
 
75 
 
Table 3.3: Physiological variables during hypercapnia and hypocapnia in the MRI session. 
 Pre 1 2 3 4 5 
Hypercapnia (11) (9) (10) (9) (9) (8) 
Heart rate (bpm) 59 ± 8 62 ± 10  66 ± 12* 67 ± 10* 68 ± 10* 69 ± 10*  
Respiration rate (breaths/minute) 13 ± 3 13 ± 3 13 ± 3 14 ± 2 15 ± 2† 14 ± 3† 
End tidal carbon dioxide (mmHg) 37 ± 3 52 ± 2* 52 ± 2* 53 ± 2* 53 ± 2* 52 ± 1* 
Hypocapnia (9) (8) (9) (8) (9) (5) 
Heart rate (bpm) 61 ± 9 70 ± 10* 68 ± 11* 67 ± 11* 67 ± 11* 67 ± 4 
Respiration rate (breaths/minute) 14 ± 3 29 ± 1* 29 ± 1* 29 ± 1* 29 ± 1* 28 ± 1* 
End tidal carbon dioxide (mmHg) 37 ± 4 24 ± 5* 25 ± 6* 24 ± 6* 24 ± 6* 25 ± 6* 
Values are mean ± SD. *p<0.05 compared to Pre. †p<0.05 compared to time 1. Sample sizes are in brackets.  
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Table 3.4: Index of wall shear stress (dyn/cm2) during hypercapnia and hypocapnia in the internal carotid (ICA) and middle cerebral 
artery (MCA). 
  Pre 1 2 3 4 5 
Hypercapnia 
ICA 3.6 ± 1.4 4.2 ± 1.6 4.7 ± 1.7* 4.8 ± 1.7* 5.0 ± 1.8*† 4.0 ± 1.0*† 
MCA 19 ± 5.6 20 ± 4.4* 23 ± 6.4*† 22 ± 4.6* 23 ± 4.9*†  23 ± 6.1*† 
Hypocapnia 
ICA 3.0 ± 0.9 2.5 ± 0.6* 2.3 ± 0.7* 2.5 ± 0.6* 2.5 ± 1.0* 2.6 ± 0.8 
MCA 17 ± 4.8 15 ± 4.9*  14 ± 5.1* 15 ± 5.4* 14 ± 5.6* 16 ± 6.9* 
Values are mean ± SD. *p<0.05 compared to Pre. †p<0.05 compared to time point 1. 
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Figure 3.1: Change in MCA and ICA indices during hypercapnia. Sample sizes at each 
time point are in brackets along the x-axis. A: MCA CSA. B: ICA CSA. There was a 
main effect of time (p=0.045) but no significant pairwise comparisons. C: Percent change 
in CSA from baseline. D: Absolute Q. E: Percent change in Q from baseline. CSA = 
cross-sectional area; CVR = cerebrovascular reactivity; ETCO2 = end tidal carbon 
Time (min) 
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dioxide; HC = hypercapnia; HO = hypocapnia; ICA = internal carotid artery; MCA = 
middle cerebral artery; Q = flow. *p<0.05 compared to Pre; †p<0.05 compared to time 1; 
‡p<0.05 compared to time 2.    
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Figure 3.2: Change in MCA and ICA indices during HO. Sample sizes at each time point 
are in brackets along the x-axis. A: MCA CSA. B: ICA CSA. C: Percent change in CSA 
from baseline. D: Absolute Q. E: Percent change in Q from baseline. CSA = cross-
sectional area; CVR = cerebrovascular reactivity; ETCO2 = end tidal carbon dioxide; HC 
= hypercapnia; HO = hypocapnia; ICA = internal carotid artery; MCA = middle cerebral 
artery; Q = flow. *p<0.05 compared to Pre; †p<0.05 compared to time 1.   
Time (min) 
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Figure 3.3: Percent change of QMCA and MCAv during changes in ETCO2. A: 
Hypercapnia. B: Hypocapnia. ETCO2 = end tidal carbon dioxide; MCAv = middle 
cerebral artery flow velocity; QMCA = middle cerebral artery flow. *p<0.05 for QMCA 
versus MCAv; †p<0.05 compared to time 1; ‡p<0.05 compared to time 2. 
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Figure 3.4: Cerebrovascular reactivity (CVR) over five minutes calculated from ICAv, 
QICA, MCAv, and QMCA during manipulations of ETCO2. A: Hypercapnia. Standard 
deviation ranges are as follows: MCAv 1.02 to 1.55 %/mmHg; QMCA 1.33 to 2.46 
%/mmHg; ICAv 1.39 to 2.04 %/mmHg; QICA 0.92 to 2.10 %/mmHg. B: Hypocapnia. 
MCAv -1.22 to -1.65 %/mmHg; QMCA -1.11 to -1.71 %/mmHg; ICAv -1.98 to -2.92 
%/mmHg; QICA -2.05 to -3.18 %/mmHg. ETCO2 = end tidal carbon dioxide; ICAv = 
internal carotid artery flow velocity; MCAv = middle cerebral artery flow velocity; QICA 
= internal carotid artery flow; QMCA = middle cerebral artery flow. 
82 
 
3.4 Discussion 
The main findings of this study are as follows: 1) The CSA of the MCA increased by the 
first minute during HC, while a decrease in MCA CSA was not observed until the fourth 
minute during HO. 2) No change was observed in ICA CSA during these HC or HO 
stimuli despite large changes in Q, flow velocity and WSS in each vessel and condition. 
3) The corresponding relative changes in QMCA and QICA were similar for both HC and 
HO. 4) The percent change in MCAv was less than the percent change in QMCA during 
HC but not HO. 5) Failure to account for MCA dilation during HC underestimated CVR 
by 58%. These results indicate that the subcortical vessels dilate rapidly, contribute 
significantly to the change in cerebral vascular conductance during HC, and are important 
to the normal CVR response during HC. Additionally, the relative change in ICA flow 
corresponded well to the ipsilateral change in MCA flow rate as would be expected. 
Overall, the data illustrate a greater vasoreactivity of the MCA versus the ICA in 
response to changes in ETCO2. 
The baseline MCA CSA values observed in this study (5.8 ± 1.1 mm2), using a 
different complement of participants, are nearly identical to those observed in our 
previous work (5.9 ± 0.8 mm2) (4). Also, the 8 ± 3%∆ in MCA diameter during HC, and 
4 ± 4%∆ during HO, of the previous study are very similar to the respective values of 8 ± 
4%and 3 ± 2% in the current study. Similarly, the average ICA baseline diameter of 5.2 ± 
0.5 mm is comparable to the values reported by Willie et al. of 5.2 ± 0.6 mm (21) and Liu 
et al. of 4.7 ± 0.7 mm (9). 
An important observation of the current study was that the rapid change in MCA 
CSA following an increase in ETCO2 was not matched by concurrent ICA dilation. The 
lack of change in ICA dimensions stands in contrast to the findings of Willie et al., who 
observed both a dilation during iso-oxic HC and constriction during iso-oxic HO (21). 
This between-study difference likely reflects the shorter stimulus used in the current 
study. Specifically, ICA diameter measurements were made during the first five minutes 
of the CO2 challenge of the current study but after at least 12 minutes in the Willie et al. 
study. Also, the magnitude of the HC stimulus was ~30% greater (65 mmHg) in the 
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Willie et al. study. Thus, the MCA appears to exert greater sensitivity to changes in 
ETCO2 than the ICA.   
The current observations have important implications for the study of CVR, a 
measurement used often as an index of cerebrovascular health (11, 15).  Many studies of 
CVR take advantage of the accessible TCD method to study MCA CBFV responses to 
HC (see Topicuoglu (16); Tsivgoulis et al (17) for review). A long-standing assumption 
of TCD is that the diameters of the large subcortical vessels being interrogated change 
little so that flow velocity is proportionate to changes in total flow. Whereas this 
assumption found support using earlier MRI devices operating at 1.5 T (14, 18), the 
improved resolution of current MRI technology exposed the reactivity of this conduit 
vessel to changes in ETCO2. Thus, reliance on CBFV data underestimates the true change 
in CBF and this, of course, would underestimate the true values of CVR during both HC 
and HO. The magnitude of this error will depend on the vasodilatory sensitivity of the 
MCA that may vary with age, sex, disease, etc.  Further, the combined data from the 
current study, our previous report (4), and that of Willie et al. (21), suggest that the 
magnitude of this error may change over the duration, and possibly dose, of the ETCO2 
challenge. These observations highlight the need for caution when interpreting CVR 
outcomes.  
In contrast to the findings during HC, MCAv did not underestimate QMCA during 
HO as we previously reported (4). The current data indicate that this constrictor pattern 
was delayed, relative to the more rapid dilation, not being observed until the fourth 
minute of HO (Figure 3B) and even then there was not a significant difference between 
the percent change in MCAv and QMCA. The slower and smaller effect of HO suggests 
that the MCA exists at a heightened level of contractile state at baseline levels of ETCO2 
such that its sensitivity for further constriction is diminished. This interpretation is 
consistent with the exponential nature of increase in CBF during the transition from HO 
to HC (4, 21). The variability in findings between studies may be due to the approach that 
highlighted the peak response in our earlier report versus the time course pattern in the 
current analysis. Also, inter-individual variability and the overall smaller response to HO 
will add to between-study variations. Another source of variability could be the 
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difference in ETCO2 between the Lab and MRI sessions. In the future, this issue could be 
resolved with clamping of ETCO2 levels to ensure that the same stimulus was attained on 
both the Lab and MRI day.  
In the current approach, the changes in flow observed in the ICA were driven 
primarily by the changes in CBFV that, in turn, resulted from dilation or constriction of 
the downstream vessels. Conversely, the changes in flow at the MCA resulted from a 
combination of the change in velocity (reflecting changes in downstream vascular 
conductance) and the change in MCA CSA. Thus, five important conclusions relevant to 
CVR assessment can be made from the current observations. First, use of velocity data 
alone underestimates the change in QMCA. Second, measures of ICA flow reflect more 
accurately the CVR outcome with HC than MCA mean flow velocity and CVR 
calculated using QICA provides a similar estimate to that calculated from QMCA when MRI 
technology is not available, at least within the timeframe of the current paradigm. Third, 
the subcortical cerebral vessels, such as the MCA, contribute importantly to the CVR 
outcome. Fourth, reactivity of cerebrovascular segments appears to increase when 
moving from the ICA to the MCA and possibly beyond. Fifth, CVR appears to change 
over time during application of a five minute stimulus and this should be considered 
when quantifying CVR. 
 This project provides, to our knowledge, the first insight into ETCO2-induced 
changes in WSS in the M1 segment of the MCA and in the ICA of humans. Of course, 
calculating WSS using a derivation of the Hagen-Poiseuille equation in human pulsatile 
flow ignores assumptions of laminar Newtonian fluid flowing through straight rigid 
cylindrical tubes. Also, the values presented here are calculated from flow data that are 
averaged over time and cannot be used to consider peak and nadir values observed during 
systole and diastole. Therefore, the values of WSS presented here must be considered to 
be approximates only and qualitative in nature. With these constraints, WSS increased 
during HC by ~40% in the ICA and 15% in the MCA. Thus, the dilatory response in the 
MCA appears to have prevented the large increase in shear stress that was present in the 
ICA. Likely, a hypercapnia induced increase in flow in blood vessels downstream to the 
MCA increased shear stress at the MCA that initiated the vasodilation.  In addition, these 
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data suggest that the ICA is relatively insensitive to acute flow-mediated dilatory stimuli. 
Based on what has been documented about the time course of flow-mediated dilation in 
the periphery, and in particular the brachial artery, peak dilation is observed around 60 
seconds after a stimulus in young subjects (2). It appears that this same flow-mediated 
mechanism does not play a role in stimulating dilation in the ICA. However, ICA dilation 
does appear to be begin near the end of the five minute CO2 stimulus (Figure 1B) 
consistent with the significant dilation observed in this vessel following 15 minutes of 
hypercapnia (21).Therefore, it seems unlikely that flow-mediated effects play a role in 
ICA dilation and at this point the reasons for this are unknown.  
This study is limited by the fact that the current design could not rule out the 
effects of blood pressure on our estimates of CSA and Q. Dynamic cerebral 
autoregulation is reduced during HC (10) resulting in greater fluctuations in CBF with 
pressure. Thus, the increase in blood pressure during HC could contribute as a stimulus 
for increased flow and, perhaps, contribute to the apparent dilation at the MCA. 
However, such an impact of blood pressure is unlikely in the current study because the 
increase in MAP at the first minute of HC was small (from 82 ± 8 to 83 ± 8 mmHg) and a 
significant dilation was already observed. Another limitation is that the MRI and Lab 
sessions were performed on different days and on average, the interval between tests was 
101 ± 74 days. In five subjects the two test days were separated by 22 days but an 
upgrade of our MRI system resulted in a delay for the remaining participants. To assess 
reproducibility, we determined CBFV CVR in one subject during HO and three subjects 
(all males) during HC on two durations separated by 29 ± 24 days. The ICC between test 
days was 0.81 (p<0.001). Additionally, we have compared estimates of CBFV on 
separate days (TCD and phase contrast imaging) that were performed 53 ± 48 days apart 
and the ICC was 0.83 (p<0.001) (4). 
Additionally, we did not control for menstrual cycle in this study. 
Cerebrovascular resistance may change over the course of the menstrual cycle (8), but 
whether or not menstrual cycle phase alters the MCA CSA response to HC remains to be 
determined. Also, we did not clamp PO2 during HC or HO. However, when measured 
independently of the current study end tidal PO2  increased from 104 ± 8 to 136 ± 4 
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mmHg during HC (n=4) and during HO from 116 ± 4 to 136 ± 5 mmHg during HO 
(n=3). Based on the findings of Willie et al. (21) we speculate that this change in PO2 
would have little effect on CBFV or CSA outcomes because an increase in arterial PO2 to 
320 mmHg only decreased MCAv by ~4 cm/s on average and decreased ICA diameter by 
0.03 cm. Lastly, the statistical power achieved for MCA CSA changes across minutes one 
to five are as follows: 0.42, 0.35, 0.71, 0.75, and 0.34, respectively. The differences in 
statistical power between the current and previous studies can be explained on the basis 
of the different methodological approach that minimized variability in the previous study. 
Specifically, in our previous work (4) the achieved power was 0.87 and was based on the 
peak response over a five minute stimulus. In contrast, the current study focused on effect 
sizes at each time point, increasing exposure to inter-individual differences in the rate of 
MCA dilation. During HO, the achieved powers are less than 0.6 at all time points due to 
a smaller overall response.   
 In summary, this study supports the conclusion that the CSA of the MCA 
increases by the first minute of HC. In contrast, the change in MCA CSA during HO was 
not detected until the fourth minute. Moreover, no changes in the CSA of the ICA were 
detected within the five minute stimulus period. Thus, in support of our previous 
findings, TCD MCAv underestimates changes in QMCA during HC but less so during HO 
(4). The similar relative changes in CBF between the ICA and MCA, suggest that the use 
of duplex ultrasound to evaluate ICA flow could be used as a surrogate measure of CVR 
when MCA diameters are not accessible. 
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Chapter 4  
4 Role of the middle cerebral artery and grey matter 
volume in cerebrovascular changes with healthy aging 
4.1 Introduction 
The cerebral vasculature is highly sensitive to alterations in the partial pressure of carbon 
dioxide (PaCO2) and in general, a lesser reactivity or change in cerebral blood flow 
velocity (CBFV) or cerebral blood flow (CBF) to a change in PaCO2 is indicative of 
increased risk of stroke and all-cause mortality and this measure is known as 
cerebrovascular reactivity (CVR) (98, 111). Age is currently the number one risk factor 
for development of cerebrovascular disease (41). It is generally well established that 
absolute CBFV as measured at the middle cerebral artery (MCA) with transcranial 
Doppler ultrasound (TCD) is reduced with healthy aging (11, 93, 134). However, there is 
conflicting evidence as to whether CVR is reduced with aging with some studies 
reporting decreased CVR with age (9, 11, 34, 132), while others reported no difference 
(35, 55, 88, 93). Some variability between studies can likely be attributed to different 
vasodilatory stimuli ranging from 5 to 7% CO2 in room air (9, 11, 34, 35, 55, 88, 93, 132) 
or 5% CO2 in 95% oxygen (9) and different modalities to acquire CBFV and CBF (TCD 
(9, 11, 34, 35, 88, 93), positron emission tomography (55), xenon inhalation (132)).  
 Examinations of CVR in healthy aging are further complicated by the fact that the 
majority of studies rely on estimates of CBFV rather than CBF. Many studies obtain 
these data using TCD that targets the MCA with the assumption that the diameter of the 
MCA does not change. However, we have documented with 3T magnetic resonance 
imaging (MRI) in two separate groups of young healthy subjects that the diameter of the 
MCA increases by approximately 8% during hypercapnia (HC) with 6% CO2 (23, 24). 
Thus, at the end of five minutes of HC, CVR calculated with CBF was 58% greater than 
CVR calculated from CBFV (24). With 7T MRI, a MCA diameter change of 7% with HC 
of 15 mmHg above baseline has also been reported (121). 
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Previous studies using TCD to examine aging and CVR have not accounted for 
MCA dilation and a possible difference in the dilatory capacity of the cerebrovasculature 
between young and older groups as cerebrovascular conductance (CVC) is reduced with 
aging (2). There is evidence that the CBF response to HC is mediated by prostaglandins 
and/or nitric oxide (NO) (11, 71). Since both of these mediators decrease with age, at 
least in the periphery (36, 112), it is possible that older adults may not have the same 
dilatory response at the MCA as young subjects. If this is the case, quantifying CVR with 
CBF rather than CBFV may expose a difference between young and older groups that is 
masked when MCA diameter changes are not taken into account. Also, it is important to 
note that CVR alone does not quantify whether the dilatory capacity of the 
cerebrovasculature is intact with age. If the end tidal CO2 (ETCO2) change is equivalent 
between groups with HC then the change in CBF is the primary determinant of CVR. 
However, an increase in CBF could be a result of a change in mean arterial pressure 
(MAP) alone. Therefore, it is necessary to examine CVC in addition to CVR to quantify 
cerebrovascular health with age.  
 Additionally, with aging, brain atrophy occurs and is more pronounced in grey 
matter (GM) than white matter (WM) (67) with certain areas within GM and WM being 
more affected than others (4, 21). Thus, when CBF is compared in a young population to 
an older population it may be difficult to draw conclusions when the volume of the 
vascular bed being perfused is unknown. Chen et al. (2011) found that regional perfusion 
quantified with arterial spin labelling and cortical thickness were not closely related 
throughout much of the cortex (18). However, these measurements are based on voxel-
level analysis and it is not clear whether this dissociation between CBF and GM volume 
holds with a more global measure of CBF, as with TCD. Therefore, the purposes of this 
study were to compare the change in cross-sectional area (CSA) of the MCA during HC 
in young adults (YA) to that in older healthy adults (OA) and to assess how these changes 
may impact estimates of CVR. We estimated brain volume, and more specifically GM 
volume, in order to determine if the reduction in CBFV and/or CBF with age is related to 
a reduction in GM volume.  
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4.2 Materials and Methods 
Ten older subjects aged 59 to 75 years (66 ± 7 years, 5 females) and 12 younger subjects 
(24 ± 4 years, range 20 to 30 years, 6 females) gave informed consent to participate in 
this study that was approved by the Health Sciences Research Ethics Board at Western 
University and performed in accordance with the Declaration of Helsinki. Subjects were 
non-smokers who had no history of cardiovascular disease. A female OA was on 10 mg 
per day of Clobazam for seizures but had not had a seizure in 13 years. Additionally, an 
older male subject was on Warfarin for a blood clot that occurred five years prior. All 
other subjects were not on any type of medications. All subjects were recreationally 
active. Female OA reported that they were postmenopausal (and this was confirmed with 
sex hormone analysis (Table 4.3)) and not on hormone replacement therapy and young 
female subjects were studied in the early follicular phase of their menstrual cycle (days 1 
to 6) or the low hormone phase of oral contraceptives (4 of 6 young female participants 
were taking oral contraceptives).  
4.2.1 Experimental Protocols 
All subjects participated in a familiarization session and two experimental sessions, 
including what will be referred to as an MRI day and a Lab day. During the 
familiarization session all experimental protocols were thoroughly explained, subjects 
practiced breathing 6% CO2, and completed the Montreal Cognitive Assessment (MoCA: 
www.mocatest.org) and the Trail Making Test to assess cognitive abilities. The MoCA is 
a 10-minute test that covers eight cognitive domains and is scored out of 30 where a score 
less than 26 indicates mild cognitive impairment (19). The Trail Making Test consists of 
Parts A and B and in Part A 25 circles are numbered from 1 to 25 and the time is 
recorded while you connect the circles numerically as fast as possible. In Part B there is a 
combination of 25 consecutive numbers and letters that must be connected alternately 
(i.e., 1-A, 2-B, 3-C, etc.) as fast as possible. Times can then be stratified into percentiles 
based on normative data (26). 
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 Prior to each experimental session subjects were asked to refrain from alcohol, 
physical activity, and caffeine for 12 hours prior to testing. For the Lab testing session, a 
blood sample was obtained after a 12-hour fast that was analyzed for blood glucose, 
hemoglobin, cholesterol, triglyceride, 17-β estradiol, progesterone, and testosterone 
concentrations. A small meal consisting of a granola bar and juice was then provided. For 
the MRI day subjects were permitted to eat a small breakfast before the testing session. 
For each day a HC trial was performed where subjects breathed air that consisted of 6% 
CO2, 21% oxygen, and 72% nitrogen. Each of these HC periods consisted of 
approximately three minutes of baseline and five minutes of HC. During HC the partial 
pressure of oxygen was not clamped.    
4.2.2 Measurements 
4.2.2.1 Lab Session 
Initially, three seated blood pressure (BP) measurements were taken (HEM-790-ITCAN, 
Omron, Lake Forest, IL, USA). Images of the right and left common carotid artery (10 
MHz probe; Vivid 7 system, GE Healthcare Canada, Mississauga, ON, Canada) were 
then captured while seated in order to quantify intima-media thickness. Throughout, heart 
rate was acquired from standard ECG. Arterial BP was measured with finger cuff 
plethysmography (Finometer, Finapres Medical Systems BV, Amsterdam, The 
Netherlands) and the brachial BPs were derived from the finger pressure waveform 
corrected to manual sphygmomanometric values. Respiration rate and ETCO2 were 
monitored with a strain gauge and a gas analyzer (ML206, ADInstruments, Colorado 
Springs, CO, USA), respectively. In the supine position, the right MCA was insonated to 
measure CBFV (2 MHz pulsed wave TCD probe; Neurovision, Multigon Industries, 
Elmsford, CA, USA) with an average depth of insonation of 4.9 ± 0.4 cm in YA and 5.0 
± 0.5 cm in OA.  
4.2.2.2 MRI Session 
MRI was performed with a 3T system (Magnetom Prisma, Siemens Medical Solutions, 
Erlangen, Germany). A 3D time of flight pulse sequence was used to identify the location 
on the M1 segment of the MCA for application of a T2 fast spin echo sequence (8 slices, 
94 
 
repetition time = 3000 ms, echo time = 96 ms, flip angle = 120°, voxel dimensions = 0.4 
x 0.4 x 2.0 mm3). The pulse sequence was gated to the peak of the pulse wave measured 
at the third finger of the right hand with an MRI-compatible pulse oximeter (8600FO 
MRI, Nonin Medical Inc., Plymouth, MN, USA). Collection of an image took 
approximately 1.25 minutes. Respiration was monitored with a strain gauge around the 
upper abdomen and ETCO2 data were collected as described during the Lab session. 
Additionally, a T1-weighted structural image was acquired with a 3D MPRAGE pulse 
sequence for determination of GM, WM, and cerebrospinal fluid volume (repetition time 
= 2.3 ms, echo time = 30 ms, flip angle = 9°, voxel dimensions = 1.0 x 1.0 x 1.0 mm).  
4.2.3 Data Analysis 
Baseline ETCO2 values from the MRI were corrected to Lab values. The length of the 
hose to the CO2 analyzer (located outside the MRI area) resulted in a damping of the 
signal that significantly diminished the baseline values. Since there was no difference in 
respiration rates between the Lab and MRI day we corrected MRI values to the average 
baseline Lab ETCO2. The MCA CSA was measured manually by two blinded observers 
using Osirix imaging software (Pixmeo, Bernex, Switzerland) and the data from both 
observers was averaged and reported. The agreement between the two observers was very 
good (intraclass correlation coefficient (ICC) was 0.987 (p<0.001)). The reported CSA 
during HC is the maximal value from the five minute period and this is reported along 
with percent change (%Δ) from baseline. All other reported variables for HC correspond 
to this maximal CSA value. When reported, the MCA diameter was calculated from the 
measured CSA. Cerebral blood flow was calculated as CBF (ml/min) = CBFV 
(cm/s)*CSA (cm2)*60 (s/min). Cerebral blood flow velocity and CBF are also reported as 
%Δ. Cerebral blood flow velocity and MCA CSA were collected at the same time of day 
on separate days and, on average, the interval between each test was 11 ± 11 days.  
 Using SPM 8 (http://www.fil.ion.ucl.ac.uk/spm/), high-dimensional spatial 
normalization was performed with T1 images using the DARTEL toolbox. A template 
was created by averaging data from all subjects. Images were then segmented into GM, 
WM and cerebrospinal fluid. Total intracranial volume was calculated as the sum of these 
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three components. Since GM volume has been documented to change the most with age 
we normalized all measurements of CBFV, CBF, CVC, and CVR to GM volume and are 
reported as CBFVGM, CBFGM, CVCGM, and CVRGM.  
 Cerebrovascular conductance was calculated as the quotient of CBFGM and MAP. 
Cerebrovascular reactivity indices were calculated both as the percent and absolute 
change in CBFGM and CBFVGM per mmHg change in ETCO2 at approximately every 
1.25 minutes during HC (to correspond with the timing of MCA images). The right and 
left common carotid artery intima-media thickness was quantified with calipers at three 
regions along the artery and averaged. An independent observer also completed the 
analysis and the ICC between the observers was 0.985 (p<0.001). An average from the 
two investigators is reported. 
4.2.4 Statistical Analysis 
The effects of time (baseline versus hypercapnia) and group (YA versus OA) were 
assessed using a general linear mixed model ANOVA and a Holm-Sidak post hoc test for 
pairwise comparisons (SigmaStat 12.0; Systat Software, San Jose, CA) for heart rate, BP, 
ETCO2, respiration, MCA CSA, CBFVGM, CBFGM, CVCGM, and CVRGM. Unpaired t-
tests were used to assess the impact of group on GM, WM and cerebrospinal fluid. The 
probability level for statistical significance was p≤0.05.  
4.3 Results 
On average, OA had greater systolic BP, fasting glucose, total and LDL cholesterol, 
triglycerides and hemoglobin A1C levels than YA but were still within the normal range 
(Table 4.1). On separate testing days (Lab and MRI) there were no differences in seated 
BP in YA or OA prior to beginning experimental protocols. Additionally, OA had greater 
intima-media thickness of the left and right common carotid arteries (Table 4.1). There 
were no differences in MoCA scores or Part B of the Trail Making Test between groups. 
Time to complete Part A of the Trail Making Test was 26 ± 10 s for the OA and 19 ± 6 s 
for the YA (p=0.07). Testosterone levels in older postmenopausal women were greater 
than YA females (p=0.03; Table 4.2) and 17-β estradiol levels were not detectable in 4 of 
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5 OA females. In the female with detectable estradiol the levels were within the 
postmenopausal range (<202 pmol/L).  
 A main effect of time (baseline to HC) was observed for heart rate and ETCO2 in 
the Lab and MRI and diastolic BP in the Lab (p<0.001 for all) (Table 4.3). A group x 
time interaction was present for systolic BP where baseline (p=0.03) and HC (p=0.002) 
systolic BP values were greater in OA versus YA and there was a significant increase 
during HC (p<0.001) in OA that was not present in YA. There were also main effects of 
time (p=0.003) and group (p=0.002) for MRI respiration where respiration was greater in 
YA compared to OA.  
There was a significant effect of time (baseline to HC) when absolute MCA CSA 
was compared to baseline but no effect of group was observed (Figure 4.1C). 
Specifically, in YA, MCA CSA increased from 6.5 ± 1.6 to 7.1 ± 1.4 mm2 with HC while 
OA CSA changed from 7.0 ± 1.2 to 7.3 ± 1.4 mm2 (Figure 4.1A and B). A significant 
difference between YA and OA was observed in %Δ CSA (p=0.04; Figure 4.1D).  
Grey matter volume was decreased in OA compared to YA (p=0.008) while WM 
volume was not different (Table 4.4). Compared to YA, cerebrospinal fluid volume was 
increased in OA (p=0.02) but the total intracranial volume was not different between 
groups. A main effect of time (p<0.001) but no effect of group was observed for 
CBFVGM where HC was greater than baseline. Similarly, for CBFGM there was a main 
effect of time (p<0.001) and no effect of group. There were significant differences in both 
YA (p<0.001) and OA (p=0.04; Figure 4.2C) when the %Δ was compared for CBFVGM 
and CBFGM where CBFVGM was lower than CBFGM.  
At baseline and during HC MAP was greater in OA than YA (p=0.01 at baseline 
and p<0.001 during HC; Figure 4.3A). Mean arterial pressure during HC was also greater 
than baseline levels within each group (p=0.02 in YA and p<0.001 in OA). At baseline 
there was no difference in CVCGM between YA and OA (Figure 4.3B). During HC, 
CVCGM was elevated in YA compared to OA (p=0.02). Additionally, within group 
differences in CVCGM were present during HC compared to baseline where there was an 
increase in CVCGM with HC (YA: p<0.001and OA: p<0.001). 
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Cerebrovascular reactivity was determined in absolute and relative terms using 
both CBFVGM and CBFGM. There was no effect of group (YA versus OA) but a 
significant difference where CBFVGM was lower when CBFGM was used for absolute 
CVRGM (p<0.001; Figure 4.4A). Relative CVRGM calculated with CBFVGM was 
decreased compared to the same estimate calculated with CBFGM in YA but not OA 
(p=0.001; Figure 4.4B).   
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Table 4.1: Subject characteristics. 
 YA OA 
n, male/female 12, 6/6 10, 5/5 
Height (cm) 173 ± 14 171 ± 12 
Weight (kg) 69 ± 14 74 ± 14 
BMI (kg/m2) 23 ± 3 25 ± 3 
Systolic BP (mmHg) 112 ± 9  123 ± 11* 
Diastolic BP (mmHg) 72 ± 6 75 ± 11 
Glucose (mmol/L) 4.8 ± 0.5 5.4 ± 0.4* 
Total cholesterol 
(mmol/L) 
3.92 ± 0.50 5.00 ± 0.77* 
HDL cholesterol (mmol/L) 1.50 ± 0.46 1.59 ± 0.45 
LDL cholesterol (mmol/L) 2.10 ± 0.47 2.94 ± 0.51* 
Triglycerides (mmol/L) 0.70 ± 0.27 1.05 ± 0.48* 
HbA1C (mmol/L) 0.053 ± 0.002 0.057 ± 0.003* 
IMT (mm)   
     Right 0.44 ± 0.05 0.73 ± 0.13* 
     Left 0.48 ± 0.06 0.74 ± 0.17* 
MoCA score (out of 30) 28 ± 1 28 ± 2 
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Trail Making Test (s) 
     Part A 19 ± 6 26 ± 10 
     Part B 41 ± 13 61 ± 33 
Values are mean ± standard deviation. BMI = body mass index; BP = blood pressure; 
HbA1C = hemoglobin A1C; HDL = high density lipoprotein; IMT = intima-media 
thickness; LDL = low density lipoprotein; MoCA = Montreal cognitive assessment; OA 
= older adults; YA = young adults. *p<0.05 versus YA. 
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Table 4.2: Sex hormones in young and older adults. 
 YA OA 
Males 
(n=6) 
Females 
(n=6) 
Males 
(n=5) 
Females 
(n=5) 
17-β Estradiol (pmol/L) 79 ± 28 125 ± 28 106 ± 34  N/A* 
Progesterone (nmol/L) 2.4 ± 1.3 1.6 ± 0.8 1.3 ± 0.6 0.8 ± 0.5  
Testosterone (nmol/L) 18.5 ± 6.3 0.9 ± 0.4 18.3 ± 7.8 0.5 ± 0.2† 
Values are mean ± standard deviation. *Four of five postmenopausal women had 17-β 
estradiol levels lower than the assay could detect (<19 pmol/L) while the remaining 
woman was 47 pmol/L. OA = older adults; YA = young adults. †p<0.05 versus YA 
females with t-test. 
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Table 4.3: Physiological characteristics at baseline and hypercapnia for Lab and MRI. 
 YA OA          P-value 
Baseline     HC Baseline HC Time Group Interaction 
LAB 
Heart rate 
(bpm) 
65 ± 9 71 ± 10 62 ± 11 68 ± 11 <0.001 0.49 0.97 
SBP 
(mmHg) 
 114 ± 10 116 ± 12  124 ± 10* 132 ± 10*† <0.001 0.07 0.04 
DBP 
(mmHg) 
68 ± 7 71 ± 7 73 ± 10 77 ± 10 <0.001 0.13 0.29 
Respiration 
(breaths per 
minute) 
13 ± 3 14 ± 5 11 ± 3 11 ± 3 0.62 0.07 0.93 
ETCO2 38 ± 4 49 ± 4 39 ± 3 49 ± 4 <0.001 0.97 0.95 
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MRI 
Heart rate 
(bpm) 
71 ± 13 78 ± 13 69 ± 15 74 ± 15 <0.001 0.57 0.42 
Respiration 
(breaths per 
minute) 
15 ± 3 17 ± 4 10 ± 4 11 ± 4 0.003 0.002 0.83 
ETCO2 38 ± 4 51 ± 2 38 ± 3 51 ± 3 <0.001 0.67 0.80 
Values are mean ± standard deviation. DBP = diastolic blood pressure; ETCO2 = end tidal carbon dioxide; HC = hypercapnia; OA = 
older adults; SBP = systolic blood pressure; YA = young adults. *p<0.05 compared to baseline. †p<0.05 compared to YA. 
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Table 4.4: Brain volume in young and older adults. 
 YA OA 
Grey matter (ml) 719 ± 98 622 ± 50* 
White matter (ml) 536 ± 60 545 ± 58 
Cerebrospinal fluid (ml) 222 ± 37 266 ± 40*  
Total intracranial volume (ml) 1476 ± 175  1432 ± 131  
Values are mean ± standard deviation. OA = older adults; YA = young adults. *p<0.05 
for baseline versus YA.  
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Figure 4.1: Middle cerebral artery cross-sectional area (CSA) during hypercapnia in 
young adults (YA) and older adults (OA). A: Mean and individual CSA at baseline and 
hypercapnia in YA. B: Mean and individual CSA at baseline and hypercapnia in OA. C: 
Mean CSA at baseline and hypercapnia in YA and OA. D: CSA percent change from 
baseline. *p<0.05 versus YA. 
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Figure 4.2: Cerebral blood flow velocity (CBFV) and cerebral blood flow (CBF) during 
hypercapnia in young adults (YA) and older adults (OA). A: CBFV at baseline and 
hypercapnia in YA and OA. B: CBF at baseline and hypercapnia in YA and OA. C: 
Percent change CBFV and CBF with hypercapnia in YA and OA. *p<0.05 versus CBFV. 
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Figure 4.3: Mean arterial pressure (A) and cerebrovascular conductance (B) at baseline 
and hypercapnia in young adults (YA) and older adults (OA). *p<0.05 versus baseline; 
†p<0.05 versus YA. 
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Figure 4.4: Cerebrovascular reactivity (CVR) at baseline and hypercapnia in young 
adults (YA) and older adults (OA). A: Absolute CVR in YA and OA. B: Relative CVR in 
YA and OA. *p<0.05 compared to CBFV CVR.  
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4.4 Discussion 
The main findings of this study are as follows: 1) The %Δ in MCA CSA with HC was 
greater in YA than OA. 2) When corrected to GM volume, MCA flow velocity or blood 
flow were not different between YA and OA at baseline or during HC. 3) CBFVGM 
underestimated the change in CBFGM with HC in both YA and OA. 4) There was a 
greater change in CVCGM during HC in YA than OA. 5) Despite the smaller dilatory 
response in OA versus YA, CVR was not different between the groups due to the 
compensatory central hemodynamic contributions to CBF through elevated BP in OA. 
Therefore, when studying MCA flow patterns, reductions in absolute baseline CBF in 
healthy aging are related to reductions in cortical mass. Furthermore, the aging process 
appears to include diminished cerebrovascular dilatory responsiveness in the MCA and 
its downstream vascular bed. In addition to exposing age-related decrements in CVC, 
these data outline the concern that the sole use of CVR to study cerebrovascular health 
may be misleading due to compensatory responses that can elevate CBF despite smaller 
dilatory responses. 
 A major finding of the current study was the smaller dilation of the MCA in OA 
in response to HC. The mechanism(s) involved in this impaired dilation is beyond the 
scope of this study but may include arterial stiffening or impaired endothelial function as 
it pertains to HC or shear stress stimuli. Extracellular pH of the cerebrovasculature is the 
main mediator of the HC-induced increase in CBF (64) via an effect on potassium 
channels (63) and it is unclear how aging may affect these channels. In addition, NO and 
prostaglandins may also play a role in this response (2, 17). Unfortunately, studying 
endothelial function in the intact, conscious human brain is difficult though drug studies 
have been employed to examine endothelial regulation of the cerebrovasculature. The 
hypercapnic increase in CBFV measured with TCD in humans (23) and CBF with the 
133Xe clearance method in rats (28) was impaired with NO synthase blockade, though not 
abolished. Additionally, administration of a NO donor to patients with endothelial 
dysfunction restores CVR measured with TCD to levels of healthy age-matched controls 
(71). However, other studies have found no effect of NO inhibition on the response to HC 
in humans (12, 29). It is possible that blockade of one pathway results in upregulation of 
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another (for example, the prostaglandin pathway) since it is not the NO pathway alone 
that is responsible for the hyperemic response to HC. Additionally, when indomethacin is 
administered to block the prostaglandin pathway in humans a difference in YA and OA in 
baseline TCD CBFV and CVR is abolished, which indicates that the prostaglandin-
mediated response to HC is impaired with aging (11).  
 This study is the first to incorporate direct measures of MCA CSA and CBF 
scaled to GM volume in calculations of flow responses in a healthy aging model. A major 
outcome of this approach was the observation that healthy aging does not affect CVR. 
Previously, reports on the impact of age on CVR were based primarily on mean CBFV 
through the MCA (2, 9, 18, 20). Yet, even CVR calculated using CBFV was the same 
between groups when normalized to GM volume. Therefore, these data highlight the 
importance of considering contributing factors to the flow response. These findings are in 
line with other human studies that have reported no difference in CVR with age using 
TCD (9, 18). Galvin et al. (2010) and Murrell et al. (2013) found no difference in CVR 
between young and older groups with a very similar age range to our subjects. However, 
MAP during HC was not reported in either of these studies so it is unclear whether a 
greater pressor response played a role in maintaining CVR in OA as we suggest based on 
our data. These studies also reported an increase in cerebrovascular resistance in the older 
participants which is in line with the reduction in conductance during HC that we 
observed in OA.  
The major outcome of this study was quantification of an age-related reduction in 
dilatory responsiveness at the MCA and the downstream vessels that it supplies. These 
data confirm the findings of Barnes et al. (2012) who drew similar conclusions based on 
TCD CBFV measures alone (11). Additionally, Barnes et al. (2012) found no differences 
in CVC between young and older adults when indomethacin was administered. These 
findings suggest that with age, one pathway that may be altered is cyclooxygenase-
mediated dilation. Our results add to these findings because they confirm that CVC 
calculated based on CBF rather than CBFV is diminished in OA. Also, the impairment in 
dilation that results in decreased CVC is not limited to vessels downstream to the MCA, 
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but also to the MCA itself. Finally, changes in GM volume with aging cannot account for 
the difference in CVC between young and older groups.     
The discussion above outlines the problem that measures of CVRGM and CVCGM 
support opposing conclusions in the context of studying human cerebrovascular health. 
These findings lead to the question of whether CVR or CVC is a more appropriate metric 
for examining the dilatory capacity of the cerebrovasculature. A major point here is that 
CVR does not measure vasodilation but only the flow response to a stimulus. In turn, 
changes in flow can be incurred by either a change in downstream conductance and/or by 
a change in the pressure gradient. The cerebrovascular pressure gradient is difficult to 
measure in humans but is formed to a large extent by the systemic BP. Nonetheless, 
rarely is BP measured or reported in CVR measures despite evidence that HC elevates BP 
(13, 20). The current study indicated that the pressor response to HC is greater in OA 
compared to YA. By accounting for changes in MAP, the current calculation of CVCGM 
exposed the reduced dilatory response in the OA. The effect of MAP on CBFV has been 
examined and reported that above a threshold ETCO2, increases in MAP with ETCO2 
have a linear relationship with CBFV (13). As well, Claassen et al. (2007) found that the 
magnitude of increase in an index of CVC with a rebreathing challenge was greater than 
the magnitude of change in CBFV which suggests that MAP has a direct effect on CBFV 
(20). Based on these findings and the fact that the change in MAP during HC was 
different between groups, we suggest that the best way to rationalize these findings is to 
calculate a CVC reactivity index as the change in CVC divided by the change in ETCO2. 
When this is done as a percent change in CVCGM there is no difference between YA (4.22 
± 1.60 %/mmHg) and OA (3.18 ± 1.34 %/mmHg, p=0.11). However, the difference is 
significant using the absolute change in CVCGM (YA: 1.8 x 10
-4 ± 0.69 x 10-4 
ml/min/ml/mmHg and OA: 1.2 x 10-4 ± 0.56 x 10-4 ml/min/ml/mmHg, p=0.04).       
 We examined the relationship between GM volume and cerebrovascular indices 
based on the idea that there is a linkage between CBF and tissue atrophy. Previous studies 
have reported decreased CBFV in OA compared to YA (2, 20, 31) and when we 
normalized CBFV to GM volume we did not see differences in CBFVGM, CBFGM, or 
CVRGM. However, a difference in CVC between groups was present during HC even 
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when normalized to GM volume. One limitation of this normalization approach is that we 
used total GM volume though the MCA is not responsible for perfusion of all the GM 
and the exact portion of tissue that it supplies is unknown. This estimate was used 
because it is difficult to determine exactly which regions are supplied by the MCA due to 
individual variation. The challenge of our approach is exposed by Chen et al. (2011) who 
examined voxel-wise measures of cortical blood flow using MRI perfusion methods 
(arterial spin labelling) and cortical thickness and reported that, on that small scale, 
reductions in CBF with aging were dissociated from the concurrent process of cortical 
atrophy (18). Therefore, our results suggest that an overall relationship exists between 
CBF and GM volume; however, the pattern becomes dissociated at the voxel scale. 
Additionally, with this cross-sectional approach we are unable to determine if initial 
atrophy results in the flow reduction or a flow impairment leads to atrophy.      
 In conclusion, this study was the first to show that the MCA and its vascular bed 
display impaired dilation to hypercapnia in healthy aging. Our studies indicate that the 
measure of CVC and/or CVC reactivity to CO2 is a more appropriate estimate of the 
dilatory capacity of the cerebrovasculature than a traditional estimate of CVR. 
Additionally, we confirm that there is a relationship between GM volume and MCA CBF 
so that a reduction in MCA CBFV and/or CBF with age may be a result of global GM 
tissue atrophy, or impaired flow leads to atrophy, and this should be accounted for when 
making comparisons between groups. 
 
 
 
 
 
 
 
112 
 
4.5 References 
1.  Bakker SL, de Leeuw FE, den Heijer T, Koudstaal PJ, Hofman A, Breteler MM. 
Cerebral haemodynamics in the elderly: the rotterdam study. Neuroepidemiology 
23: 178–184, 2004. 
2.  Barnes JN, Schmidt JE, Nicholson WT, Joyner MJ. Cyclooxygenase inhibition 
abolishes age-related differences in cerebral vasodilator responses to hypercapnia. 
J Appl Physiol 112: 1884–1890, 2012. 
3.  Battisti-Charbonney A, Fisher J, Duffin J. The cerebrovascular response to carbon 
dioxide in humans. J Physiol 589: 3039–3048, 2011. 
4.  Chen JJ, Rosas HD, Salat DH. Age-associated reductions in cerebral blood flow 
are independent from regional atrophy. Neuroimage 55: 468–478, 2011. 
5.  Claassen JA, Zhang R, Fu Q, Witkowski S, Levine BD. Transcranial Doppler 
estimation of cerebral blood flow and cerebrovascular conductance during 
modified rebreathing. J Appl Physiol 102: 870–877, 2007. 
6.  Coverdale NS, Gati JS, Opalevych O, Perrotta A, Shoemaker JK. Cerebral blood 
flow velocity underestimates cerebral blood flow during modest hypercapnia and 
hypocapnia. J Appl Physiol 117: 1090–1096, 2014. 
7.  Coverdale NS, Lalande S, Perrotta A, Shoemaker JK. Heterogeneous patterns of 
vasoreactivity in the middle cerebral and internal carotid arteries. Am J Physiol 
Heart Circ Physiol. (February 27, 2015). doi: 10.1152/ajpheart.00761.2014. 
8.  Fluck D, Beaudin AE, Steinback CD, Kumarpillai G, Shobha N, McCreary CR, 
Peca S, Smith EE, Poulin MJ. Effects of aging on the association between 
cerebrovascular responses to visual stimulation, hypercapnia and arterial stiffness. 
Front Physiol 5: 49, 2014. 
113 
 
9.  Galvin SD, Celi LA, Thomas KN, Clendon TR, Galvin IF, Bunton RW, Ainslie 
PN. Effects of age and coronary artery disease on cerebrovascular reactivity to 
carbon dioxide in humans. Anaesth Intensive Care 38: 710–717, 2010. 
10.  Gerhard M, Roddy M, Creager S, Creager M. Aging progressively impairs 
endothelium-dependent vasodilation in forearm resistance vessels of humans. 
Hypertension 27: 849–853, 1996. 
11.  Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, 
Creager MA, Culebras A, Eckel RH, Hart RG, Hinchey JA, Howard VJ, Jauch EC, 
Levine SR, Meschia JF, Moore WS, Nixon JVI, Pearson TA. Guidelines for the 
primary prevention of stroke: a guideline for healthcare professionals from the 
American Heart Association/American Stroke Association. Stroke 42: 517–584, 
2011. 
12.  Ide K, Worthley M, Anderson T, Poulin MJ. Effects of the nitric oxide synthase 
inhibitor L-NMMA on cerebrovascular and cardiovascular responses to hypoxia 
and hypercapnia in humans. J Physiol 584: 321–332, 2007. 
13.  Ito H, Kanno I, Ibaraki M, Hatazawa J. Effect of aging on cerebral vascular 
response to PaCO2 changes in humans as measured by positron emission 
tomography. J Cereb Blood Flow Metab 22: 997–1003, 2002. 
14.  Kitazono T, Faraci F, Taguchi H, DD H. Role of potassium channels in cerebral 
blood vessels. Stroke 26: 1713–1723, 1995. 
15.  Kontos HA, Raper AJ, Patterson JL. Analysis of vasoactivity of local pH, PCO2 
and bicarbonate on pial vessels. Stroke 8: 358–360, 1977. 
16.  Kruggel F. MRI-based volumetry of head compartments: normative values of 
healthy adults. Neuroimage 30: 1–11, 2006. 
17.  Lavi S, Gaitini D, Milloul V, Jacob G. Impaired cerebral CO2 vasoreactivity: 
association with endothelial dysfunction. Am J Physiol Circ Physiol 291: H1856–
1861, 2006. 
114 
 
18.  Murrell CJ, Cotter JD, Thomas KN, Lucas SJ, Williams MJ, Ainslie PN. Cerebral 
blood flow and cerebrovascular reactivity at rest and during sub-maximal exercise: 
effect of age and 12-week exercise training. Age 35: 905–920, 2013. 
19.  Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, 
Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: A brief 
screening tool for mild cognitive impairment. J Am Geriatr Soc 53: 695–699, 
2005. 
20.  Oudegeest-Sander MH, van Beek AHEA, Abbink K, Olde Rikkert MGM, Hopman 
MTE, Claassen JAHR. Assessment of dynamic cerebral autoregulation and 
cerebrovascular CO2 reactivity in ageing by measurements of cerebral blood flow 
and cortical oxygenation. Exp Physiol 99: 586–598, 2014. 
21.  Pfefferbaum A, Rohlfing T, Rosenbloom M, Chu W, Colrain I, Sullivan E. 
Variation in longitudinal trajectories of regional brain volumes of healthy men and 
women (ages 10 to 85 years) measured with atlas-based parcellation of MRI. 
Neuroimage 65: 176–193, 2013. 
22.  Portegies ML, de Bruijn RF, Hofman A, Koudstaal PJ, Ikram MA. Cerebral 
vasomotor reactivity and risk of mortality: the Rotterdam Study. Stroke 45: 42–47, 
2014. 
23.  Schmetterer L, Findl O, Strenn K, Graselli U, Kastner J, Eichler H, Wolzt M. Role 
of NO in the O2 and CO2 responsiveness of cerebral and ocular circulation in 
humans. Am J Physiol Integr Comp Physiol 273: R2005–R2012, 1997. 
24.  Silvestrini M, Vernieri F, Pasqualetti P, Matteis M, Passarelli F, Troisi E, 
Caltagirone C. Impaired cerebral vasoreactivity and risk of stroke in patients with 
asymptomatic carotid artery stenosis. JAMA 283: 2122–2127, 2000. 
25.  Singh N, Prasad S, Singer DRJ, MacAllister R. Ageing is associated with 
impairment of nitric oxide and prostanoid dilator pathways in the human forearm. 
Clin Sci (Lond) 102: 595–600, 2002. 
115 
 
26.  Tombaugh TN. Trail Making Test A and B: normative data stratified by age and 
education. Arch Clin Neuropsychol 19: 203–214, 2004. 
27.  Verbree J, Bronzwaer A-SGT, Ghariq E, Versluis MJ, Daemen MJAP, van 
Buchem MA, Dahan A, van Lieshout JJ, van Osch MJP. Assessment of middle 
cerebral artery diameter during hypocapnia and hypercapnia in humans using ultra-
high-field MRI. J Appl Physiol 117: 1084–1089, 2014. 
28.  Wang Q, Paulson OB, Lassen NA. Effect of nitric oxide blockade by NG-Nitro-L-
Arginine on cerebral blood flow response to changes in carbon dioxide tension. J 
Cereb Blood Flow Metab 12: 947–953, 1992. 
29.  White RP, Deane C, Vallance P, Markus HS. Nitric oxide synthase inhibition in 
humans reduces cerebral blood flow but not the hyperemic response to 
hypercapnia. Stroke 29: 467–472, 1998. 
30.  Yamamoto M, Meyer JS, Sakai F, Yamaguchi F. Aging and cerebral vasodilator 
responses to hypercarbia: responses in normal aging and in persons with risk 
factors for stroke. Arch Neurol 37: 489–496, 1980. 
31.  Zhu YS, Tarumi T, Tseng BY, Palmer DM, Levine BD, Zhang R. Cerebral 
vasomotor reactivity during hypo- and hypercapnia in sedentary elderly and 
Masters athletes. J Cereb Blood Flow Metab 33: 1190–1196, 2013.  
 
 
 
 
 
 
116 
 
Chapter 5  
5 General Discussion 
5.1 Perspectives 
A literature search in PubMed using the search term “transcranial Doppler ultrasound” 
elicits a response of almost 8,000 papers. A majority of these papers examine the MCA 
and all assume that the diameter of the MCA does not change or that the change is 
negligible so CBFV is the same as CBF. Hypercapnia and/or hypocapnia are commonly 
used to examine cerebrovascular health where a greater increase in CBFV with HC 
and/or a greater decrease in CBFV with HO is a healthier response. Based on evidence 
that MCA diameter may not be constant combined (2, 4) with a greater availability of 
MRI technology with enhanced resolution we designed this series of studies to examine 
how MCA CSA changes with HC or HO. Additionally, we wanted to quantify how 
changes in MCA CSA impact estimates of CBF and CVR in young and older 
populations. Finally, we examined how changes in MCA CSA compare to those at the 
ICA with HC and HO.  
5.2 Major Findings 
The main finding of this series of studies were that MCA CSA increased during HC and 
decreased during HO. When the findings from all three studies using HC (n=36) and the 
two studies with HO (n=24) for young adults were combined the average increase was 15 
± 8% during HC and the average decrease was 9 ± 6% during HO (Figure 5.1). When 
CBFV was compared to CBF during HC, CBFV underestimated the change in CBF. 
Also, CVR during HC was underestimated if CBFV was used. In the first study of this 
series we documented similar results with HO where CBFV underestimated the change in 
CBF and CVR. However, in the second study of this series the difference between CBF 
and CBFV was not significant during HO. Additionally, even in OA where the change in 
CSA was smaller during HC, this still resulted in a greater change in CBF versus CBFV. 
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 When the CSA data from all studies are combined (Figure 5.1) an important 
observation is that there is variability in the data both in baseline CSA and in the response 
HC and HO. Initially, we were hopeful that a universal correction factor could be applied 
so that TCD users could correct CBFV measurements based on the amount of change in 
ETCO2 to more closely estimate CBF; however this is not practical because of the 
variability in the response. For example, in the subject with the largest baseline CSA 
(who also had the smallest response to HC), during HC there was no diameter change so 
CBFV is equivalent to CBF. However, in the subject with the greatest hypercapnic 
response, the MCA CSA change was almost 29% resulting in a 42% difference in 
estimates of CBFV and CBF. During HO, there were also subjects who had almost no 
constriction at the MCA while the greatest change was a 22% decrease which resulted in 
an 11% difference in CBFV and CBF.    
Comparison of diameter changes at the MCA to the ICA during HC and HO 
revealed that the dilation/constriction response is greater at the MCA as no change was 
observed in ICA diameter. This difference was not expected as Willie et al. (2012) had 
documented changes in ICA diameter with HO and HC (5). Different exposure times to 
HC and HO likely played a role in these observations as we did HC and HO for five 
minutes while Willie et al. (2012) applied each stimulus for 12 to 15 minutes before 
measurement for CBFV (5). Future studies could examine MCA CSA over longer 
exposure to HC and HO. Another notable finding from this study was that at the end of 
five minutes, CVR calculated with ICA CBF produced similar estimates to those from 
MCA CBF. Since ICA CBF can be quantified with duplex ultrasound and does not 
require MRI technology this method of determining CVR is likely more feasible than 
performing TCD to determine CBFV and then MRI to determine MCA CSA.   
Lastly, CBFV, CBF, and CVR normalized to GM volume were not different 
between young and older adults while CVCGM and the percent change in MCA CSA was 
greater in YA during HC. In this study, during HC there was a greater pressor response in 
OA (7 ± 5 mmHg) versus YA (3 ± 3 mmHg) which we believe compensated for 
decreased dilation at the MCA to equalize CBF between groups. Based on these findings, 
we suggest that CVC or CVC reactivity (ΔCVC/ΔETCO2) is a more appropriate measure 
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to examine the dilatory capacity of the cerebrovasculature as it accounts for changes in 
MAP. Even with 4% CO2, Barnes et al. (2012) reported, on average, a change in MAP 
from 81 ± 5 to 84 ± 5 mmHg which suggests that even with a smaller stimulus a change 
in pressure cannot be avoided (1). Examining the mechanism behind reduced 
cerebrovascular dilation was beyond the scope of this research. However, previous work 
has implicated a lack of production or utilization of prostaglandins and/or NO in the 
response to HC by examining CBFV with TCD (1, 3). Therefore, this same study design 
could be used to examine CVC in populations with poor endothelial health, such as those 
with atherosclerosis.  
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Figure 5.1: Change in middle cerebral artery (MCA) cross-sectional area (CSA) during 
hypercapnia (A) and hypocapnia (B). 
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5.3 Utility of Transcranial Doppler Ultrasound 
It is important to identify how these changes in MCA CSA during HC and HO may 
impact the findings of many TCD studies as MRI technology is not as widely accessible 
or feasible. When examining differences between groups and/or experimental conditions 
that involve HC or HO it is important to recognize that measured changes in CBFV likely 
underestimate actual changes in CBF. However, this is more of a problem when 
comparing groups that likely have differences in arterial health. For example, in the third 
study in this thesis young and older adults did not have the same dilatory response at the 
MCA to HC so we cannot say that CBFV underestimates CBF by the same amount in 
each group. Based on our findings in OA we speculate that other groups of older adults 
such as those with cardiovascular disease likely have a similar, or possibly even greater, 
impairment in MCA dilation. Therefore, when comparing such a group to a young 
population it is more important to keep in mind that changes in the MCA are likely 
different between groups. In terms of HO, the constrictor response at the MCA was 
smaller than the dilatory response to HC so changes at the MCA have less of an impact 
on CBF with HO. For instance, in the second study of this thesis when the changes in 
CBFV versus CBF were compared over five minutes, no significant changes in HO CSA 
were detected until minute four. Therefore, for the first three minutes of HO there is little 
difference between CBFV and CBF. Consequently, employing HO protocols that are 
shorter in duration is the best way to minimize differences in CBFV versus CBF. 
Additionally, if the study population consists of all OA then we have established that 
there is less CSA change even with HC so in this case CBFV is a better indicator of CBF.  
 Finally, TCD is unmatched in its time resolution. In our studies, a difference in 
MCA CBFV could be observed within 30 seconds of initiation of HC or HO and tracked 
beat-by-beat. This is in contrast to our MRI measurement of phase contrast CBFV that 
took approximately 2.5 minutes to create the velocity profile over one cardiac cycle or 
our measurement of CSA that could be captured every 1 to 1.25 minutes. Therefore, the 
aim of these studies was not to imply that TCD is not a useful tool but to encourage 
examination into some of the basic assumptions of the technique. Application of TCD 
during changes in ETCO2 can still be encouraged though possible changes in diameter 
121 
 
should be considered in terms of designing a study that minimizes the impact of these 
changes so that CBFV more closely predicts CBF.  
5.4 Conclusions 
In young adults, the MCA dilates by the first minute of hypercapnia and this dilation 
means that CBFV underestimates both CBF and CVR. In contrast, the MCA does not 
constrict during hypocapnia until the fourth minute and the impact of this constriction on 
estimates of CBF and CVR is less than that of hypercapnia. In addition, constriction and 
dilation at the MCA is unmatched by similar responses at the ICA. Finally, the CVR 
response to hypercapnia is preserved in healthy older adults, compared to young. 
However, impaired MCA dilation and CVC in older adults suggests that the dilatory 
capacity of the cerebrovasculature is impaired in comparison to young adults. Therefore, 
we suggest that CVC or CVC reactivity is a more telling estimate of the health of the 
cerebrovasculature than CVR.  
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LETTER OF INFORMATION 
Project Title: Examining flow and diameter in the middle cerebral artery during different 
levels of carbon dioxide, lower body negative pressure and nitroglycerin. 
Principal Investigator:  J. Kevin Shoemaker, Ph.D. 
Research Coordinator:  Nicole Coverdale, M.Sc.   
                                         Katelyn Norton, M.Sc. 
                                         Carly Barron, M.Sc. 
Sponsor: CIHR team grant in physical activity, mobility and neural health 
This letter of information is part of the process of informed consent. It should give you an 
understanding of the research being conducted and what your participation will involve. 
If you would like more details regarding something mentioned in this letter, or 
information not included here, please ask. Take time to read this carefully and to know 
the following information. You will receive a copy of this form to keep as your own. 
Introduction 
You are invited to voluntarily participate in a research study that examines how blood 
vessels in your brain respond to different protocols by using imaging techniques. A 
variety of stressors change blood flow in the brain and it is currently unclear whether this 
is because the large blood vessels are changing diameter in response to such stressors. 
Therefore, the main purpose of the study is to measure the diameter of and flow through 
larger brain vessels with magnetic resonance imaging (MRI). As well, a type of 
ultrasound called transcranial Doppler (TCD) is commonly used to study brain blood 
flow often based on the assumption that large vessel diameter does not change. 
Therefore, a secondary purpose of this study is to validate TCD measures of blood flow 
velocity against MRI measures. The study contains three parts that will be conducted on 
three separate days. A total of 60 participants will be recruited in this study. If you agree 
to participate, you will be required to come to the laboratory approximately three hours 
following a light meal and after having avoided alcohol, Nicorette gum, coffee, tea, soft 
drinks and chocolate for at least 12 hours.  
Participant Inclusion/Exclusion Criteria 
You will not be included in the study if you are not within the age ranges of 18 and 80 
years of age or if you have any of the following: Raynaud’s disease, respiratory illnesses, 
glaucoma, claustrophobia, metallic implants or objects in or under your skin. You will 
not be included in the study if you are a smoker. In addition, you will not be included in 
the study if you are, or think you might be, pregnant. Also, you will not be included in the 
study if you have taken phosphodiesterase type 5 inhibitors within the last 24 hours. This 
class of drugs includes Viagra, Cialis, and Levitra and are used for the treatment of 
erectile dysfunction. There is a risk for decreased blood pressure due to the 
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administration of nitroglycerin in this study and ingestion of these types of drugs magnify 
this risk. Additionally, since MRI is used in this study, you will not be included in the 
study if you are not suitable for MRI based on the following criteria: 
MRI exclusion criteria 
If you have any history of head or eye injury involving metal fragments, if you have 
some type of implanted electrical device (such as a cardiac pacemaker), if you have 
severe heart disease (including susceptibility to heart rhythm abnormalities), you should 
not have an MRI scan unless supervised by a physician. Additionally you should not have 
a MRI scan if you have conductive implants or devices such as skin patches, body 
piercing or tattoos containing metallic inks because there is a risk of heating or induction 
of electrical currents within the metal element causing burns to adjacent tissue. 
Research Tests  
If you take part in this study, you will report to the laboratory on separate occasions to 
complete two phases (and 3 Days) of the study.  The following addresses what will 
happen on each day of testing. 
Day 1 Instrumentation: Laboratory for Brain and Heart Health, Room 402, Labatt 
Health Sciences Building.   
For the tests that occur at the Laboratory for Brain and Heart Health you will have the 
following devices attached to you/tests performed for data collection: 
 
1.  A button ultrasound probe will be held against the temple region of your head that 
will determine how fast the blood is flowing through one of the larger vessels in 
the brain. This process is known as transcranial Doppler ultrasound. 
2.  Small electrodes will be placed on your chest to record the electrocardiogram 
(ECG, the heart rate tracing).   
3.  A small cuff will be placed around one finger and a blood pressure cuff will be 
placed around the upper portion of the same arm.  These cuffs are used to measure 
your blood pressure.  When activated, the finger cuff will inflate with air and you 
should feel a pulsating sensation on your finger.  During a recording session your 
finger may turn slightly blue and feel numb but this quickly goes away when the 
cuff pressure is reduced. 
4.  An elastic strap will be placed around your chest to monitor changes in breathing 
rate and depth. No discomfort or risks are associated with this procedure. 
5.  You will be fitted with a small mouthpiece so that you can breathe a mixture of 
gas that is mostly oxygen but contains a higher than normal level of carbon 
dioxide.  Breathing the carbon dioxide will last a minimum of 7 to 8 minutes. 
6.  You will be asked to breathe faster than normal, in time with a metronome. 
7.  You will undergo a procedure called “lower body negative pressure (LBNP)”. In 
this procedure your legs and hips are sealed in a box and a vacuum will create 
suction around your lower body to mimic the effects of gravity. This lower body 
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suction mimics the effect of upright posture and, depending on the degree of 
suction, unloads baroreceptors in the heart and/or in the aortic arch and carotid 
sinus. The level of suction that will be used is equivalent to the effect of gravity 
when sitting up.   
8.  An anesthetist will insert a small plastic tube (catheter) into a large vein in your 
arm or hand. This catheter will be connected to an intravenous tube through which 
the anesthetist will infuse a drug called nitroglycerin (used to treat angina) or a 
saline solution that simply mimics the water portion of your blood.  Any infusion 
will last up to 15 minutes.  
9.  You will be asked to breathe through an inspiratory impedance threshold device 
(ITD) attached to a tube. You will experience some resistance while inhaling 
through this device.  
 
Day 1 Experimental Procedures (Summarized in Figure 1) 
 
You will undergo 5 experimental tasks: 1) Breathing higher-than-normal carbon dioxide 
(6% CO2, 21% oxygen and balanced nitrogen), 2) hyperventilating (to reduce carbon 
dioxide in your blood), 3) LBNP 4) nitroglycerin administration and 5) ITD. Tossing a 
coin will randomize the order of the first three protocols.  
 
1. Carbon dioxide: a facemask will be attached through which you will breathe 
air with the same amount of oxygen as with normal air but with more carbon 
dioxide. Carbon dioxide levels will be monitored from a line attached to the 
facemask. After 5 minutes of rest, you will breathe CO2 until end tidal partial 
pressure of CO2 (PETCO2) reaches 50 mmHg (about 2-3 minutes), after which 
you will continue breathing the gas for 5 minutes for a total of 7 to 8 minutes. 
This level of CO2 will make you breathe faster and deeper. Five minutes 
recovery will then allow your levels of carbon dioxide to return to normal. 
2. Hyperventilation: after a 5 minutes rest period, you will be asked to breathe in 
time with a metronome at a rate that is faster than your normal breathing rate.  
You will then be given 5 minutes to recover. 
3. LBNP: after 5 minutes of rest, suction will be turned on for 5 minutes and this 
will be followed by 5 minutes of recovery. 
4. Saline and nitroglycerin: in a random assignment (like the tossing of a coin) 
saline or nitroglycerine will be infused. Saline will be infused for 5 minutes 
and nitroglycerine (0.5 μg/kg/min) will continue for 15 minutes. Five minutes 
of recovery will end the test.  
5. ITD: You will be asked to breathe through a tube with an attached ITD for 1-5 
minutes at rest and during LBNP.  
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The protocols will take approximately 75 minutes for the actual experiment plus time for 
equipment setup, insertion of the catheter, familiarization with the protocol and recovery 
from the nitroglycerin. Also, it is expected that the TCD probe will continually need to be 
adjusted slightly to maximize the quality of the signal. Therefore, the entire test time is 
expected to be about 3 hours. 
Days 2 and 3 Instrumentation: Robarts Research Institute at Western University 
For the tests that occur at the Robarts Research Institute you will have the following 
devices attached to you/tests performed for data collection: 
 
1.  The blood vessels in your brain will be imaged, which means that you will lie on 
a table that enters the bore of a 3.0 Tesla whole-body MRI. It can be noisy during 
the MRI procedure so you will wear hearing protection (head phones). 
2.  A small cuff will be placed around one finger and will measure heart rate.  
3.  An elastic strap will be placed around your chest to monitor changes in breathing 
rate and depth. No discomfort or risks are associated with this procedure. 
4.  You will be fitted with a small mouthpiece so that you can breathe a mixture of 
gas that is mostly oxygen but contains a higher than normal level of carbon 
dioxide.  Breathing the carbon dioxide will last a minimum of 7 to 8 minutes. 
5.  You will be asked to breathe faster than normal, in time with a metronome. 
6.  You will undergo a procedure called “lower body negative pressure (LBNP)”. In 
this procedure your legs and hips are sealed in a box and a vacuum will create 
suction around your lower body to mimic the effects of gravity. This lower body 
suction mimics the effect of upright posture and, depending on the degree of 
suction, unloads baroreceptors in the heart and/or in the aortic arch and carotid 
sinus. The level of suction that will be used is equivalent to the effect of gravity 
when sitting up.  
7.  An anesthetist will insert a small plastic tube (catheter) into a large vein in your 
arm or hand. This catheter will be connected to an intravenous tube through which 
the anesthetist will infuse a drug called nitroglycerin (used to treat angina) or a 
saline solution that simply mimics the water portion of your blood.  Any infusion 
will last up to 15 minutes.  
8.  You will be asked to breathe through an inspiratory impedance threshold device 
(ITD) attached to a tube. You will experience some resistance while inhaling 
through this device.  
Days 2 and 3 Experimental Procedures (Summarized in Figure 1) 
You will undergo 5 experimental tasks: 1) Breathing higher-than-normal carbon dioxide 
(6% CO2, 21% oxygen and balanced nitrogen), 2) hyperventilating (to reduce carbon 
dioxide in your blood), 3) LBNP, 4) nitroglycerin administration and 5) ITD. Tossing a 
coin will randomize the order of these tasks. 
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1. Carbon dioxide: a facemask will be attached through which you will breathe 
air with the same amount of oxygen as with normal air but with more carbon 
dioxide. Carbon dioxide levels will be monitored from a line attached to the 
facemask. After 5 minutes of rest, you will breathe CO2 until end tidal partial 
pressure of CO2 (PETCO2) reaches 50 mmHg (about 2-3 minutes), after which 
you will continue breathing the gas for 5 minutes for a total of 7 to 8 minutes. 
This level of CO2 will make you breathe faster and deeper. Five minutes 
recovery will then allow your levels of carbon dioxide to return to normal. 
2. Hyperventilation: you will continue wearing the facemask during this 
protocol. After a 5 minutes rest period, you will be asked to breathe in time 
with a metronome at a rate that is faster than your normal breathing rate. You 
will then be given 5 minutes to recover. 
3. LBNP: after 5 minutes of rest, suction will be turned on for 5 minutes and this 
will be followed by 5 minutes of recovery. 
4. Saline and nitroglycerin: in a random assignment (like the tossing of a coin) 
saline or nitroglycerine will be infused. Saline will be infused for 5 minutes 
and nitroglycerine (0.5 μg/kg/min) will continue for 15 minutes. Five minutes 
of recovery will end the test.  
5. ITD: You will be asked to breathe through a tube with an attached ITD for 1-5 
minutes at rest and during LBNP.  
The protocols will take approximately 75 minutes for the actual experiment plus time for 
equipment setup, insertion of the catheter, familiarization with the protocol and recovery 
from the nitroglycerin. Therefore, the entire test time is expected to be about 2 hours. 
 
 
 
 
  
Figure 1. Study protocol. 
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Risks 
MRI 
Part of your participation in this study will involve a research test with Magnetic 
Resonance Imaging (MRI) system, a common medical diagnostic tool that uses a strong 
magnetic field, a low frequency magnetic field, and a radio frequency field. No X-rays 
are used. As with any technology there is a risk of death or injury. For MRI the risk of 
death is less than 1 in 10 million and the risk of injury is less than 1 in 100,000. These 
risks do not arise from the MRI process itself, but from a failure to disclose or detect MRI 
incompatible objects in or around the body of the subject or the scanner room. It is 
therefore very important that you answer all the questions honestly and fully on the MRI 
screening questionnaire. 
Almost all the deaths and injuries related to MRI scans have occurred because the MRI 
operator did not know that surgically implanted metal hardware (such as a cardiac 
pacemaker) was present inside the subject during the MRI scan. Other remote risks 
involve temporary hearing loss from the loud noise inside the magnet. This can be 
avoided with ear headphone protection that also allows continuous communication 
between the subject and staff during the scan. 
For comparison, the risk of death in an MRI is similar to travelling 10 miles by car, while 
the risk of injury during an MRI is much less than the risks associated with normal daily 
activities for 1 hour. 
You may not be allowed to continue in this research study if you are unable to have a 
MRI scan because, for example, you have some MRI incompatible metal in your body, 
you may be pregnant or attempting to become pregnant, or you may have a drug patch on 
your skin that contains a metal foil. Should you require a medically necessary MRI scan 
in the future, the final decision as to whether you can be scanned will be made by a 
qualified physician considering all the risks and benefits. 
Venous Catheter 
There is a small risk of bruising or infection when inserting the catheter into your vein.  
Some patients may experience mild pain and discomfort and some may feel nauseated or 
dizzy when blood is taken. 
ECG 
The adhesive on the electrodes used to measure your heart rate may cause a small rash to 
develop under the electrode.  However, this rash should disappear in a day or two. 
Blood pressure cuff 
There are no known risks of using the finger cuff methods (Finometer) of examining 
arterial blood pressure. With the finger cuff the fingertip may turn a little blue and feel 
numb during the prolonged test sessions but this resolves immediately when the cuff is 
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removed. Standard arm cuff blood pressure measures of arterial pressure will also be 
obtained periodically, a method that has no known risks. 
Transcranial Doppler ultrasound 
There are no known harmful effects with standard diagnostic ultrasound and tonometry as 
used in this study.  
CO2 Breathing 
Breathing a slightly higher level of carbon dioxide may give you a small headache and it 
may make you feel breathless.  These feelings vanish quickly when you start breathing 
room air again.  
Lower Body Negative Pressure 
As an orthostatic stress, LBNP carries a risk of fainting (syncope). This is particularly 
important during prolonged levels (i.e., 5-10 minutes). To reduce the risk of syncope you 
will be instructed to inform the experimenters if you feel any of the symptoms of 
presyncope (i.e. nausea, light headedness, tunnel vision, blurry vision, excessive heat and 
sweat).  You will also be monitored throughout the test for the following termination 
criteria: systolic blood pressure less than 90 mmHg, sudden reductions in systolic blood 
pressure of >20 mmHg, sudden decrease in heart rate or heart rate less than 30 bpm and 
symptoms suggestive of impending syncope. There is minimal risk to you for the 
duration and level of LBNP used here because mean arterial pressure is minimally 
threatened and there is no additional challenge to cerebral perfusion.  Also note that 
syncope does not develop immediately even in full head-up tilt tests.  Moreover, the signs 
of imminent syncope generally develop 1-2 minutes prior to the event (i.e., generally, 
there is a progressive reduction in blood pressure prior to the sudden hypotension that 
marks presyncope). We will monitor you for these symptoms and stop the suction upon 
their first appearance. 
Inspiratory impedance Threshold Device  
There are no known harmful effects associated with breathing through the ITD as used in 
this study.  
Nitroglycerin 
Nitroglycerin may induce headache. A headache occurs in up to 50% of patients as a 
result of dilation of brain blood vessels. The headache usually disappears within several 
days with continued treatment. Acetaminophen (Tylenol) may be used to treat nitrate 
headaches. Other adverse reactions that occur in less than 1% of patients include allergy: 
itching, wheezing, tracheobronchitis (inflammation of lower respiratory tract); 
cardiovascular: hypotension (low blood pressure), reflex tachycardia (increased heart 
rate), palpitations (abnormality of regular heart rhythm), bradycardia (slowed heart rate), 
syncope due to nitrate vasodilation has rarely been reported; central nervous system: 
headache, weakness, dizziness, apprehension, restlessness; gastrointestinal: nausea, 
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vomiting, diarrhea, and abdominal pain; genitourinary: dysuria (difficulty urinating), 
urinary frequency, impotence; metabolic: methemoglobinemia (abnormal amount of a 
form of hemoglobin is produced); musculoskeletal: arthralgia (joint pain), muscle 
twitching; ophthalamologic: blurred vision; respiratory: bronchitis, pneumonia, upper 
respiratory symptoms. 
Staying still  
During the experiment, you have to remain still in a lying down position for 3 hours. You 
may develop a sore back in the middle of the experiment. These sensations will diminish 
very quickly when you sit up from the bed after the experiment. 
Alternatives to Participating 
You may choose not to participate in this study. 
Benefits to You if You Take Part in the Study 
There are no direct benefits to you as a result of the study.  
Voluntary Participation 
You are encouraged to ask questions regarding the purpose of this study and the outcome 
of your testing.  Participation in this study is voluntary.  You may refuse to participate, 
refuse to answer any questions, or withdraw from the study at any time with no effect on 
your academic or employment status.  We ask that you do not get involved in any other 
study while you are involved in this study.  However, participation in this study will not 
stop you from being involved in future studies. You do not waive any legal rights by 
signing the consent form.  
Incidental Findings 
An incidental finding refers to any unexpected observation made during the course of the 
study that may require attention by your doctor. Examples could include high blood 
pressure, irregular heart rhythm or a mass observed with MRI. Should an abnormality be 
detected during testing, you will be informed and will be encouraged to share this 
information with your doctor.  
Confidentiality 
All information that you provide will be keep strictly confidential. No information that 
could reveal your identity will be released to anyone unless disclosure is required legally. 
All of the information collected for this study will be stored in a locked filing cabinet that 
will only be accessible to the research team. To further protect your anonymity, your 
name will be replaced with a subject ID number on all documents. Representatives of 
The University of Western Ontario Health Sciences Research Ethics Board may require 
access to your study-related records or may follow up with you to monitor the conduct of 
the research. 
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Compensation 
You will be compensated for parking expenses. 
Publication of Results 
Published results from this study will not identify you by name.  New findings from this 
study may be forwarded to each interested participant upon request.  You may keep a 
copy of this letter of information. 
Contact Persons 
If you have any questions regarding this study, please feel free to contact:  
Dr. Kevin Shoemaker 
(519) 661-2111 Ex 85759 
Room 3110 Thames Hall 
Western University 
 
If you have any questions about your rights as a participant or about the conduct of the 
study you may contact The University of Western Ontario Office of Research Ethics, 
519-661-3036 or email ethics@uwo.ca 
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LETTER OF INFORMED CONSENT 
Project Title:  
Examining flow and diameter in the middle cerebral artery during different levels of 
carbon dioxide, lower body negative pressure and nitroglycerin. 
Principal Investigator:  
J. Kevin Shoemaker, Ph.D. 
I have read the letter of information, have had the nature of the study explained to 
me and I agree to participate.  All questions have been answered to my satisfaction.  
SIGNATURES 
In the event that abnormal findings are observed during any of the tests, or upon my 
wishes, I consent to the release of my medical information to my family doctor or 
medical clinic. 
Name of Doctor or Clinic  
 
I agree   OR  I disagree   
 (initial) (initial) 
 
 
Name of participant (Please print)                                  Name of person obtaining consent 
 
 
Signature of participant                                             Signature of person obtaining consent 
 
 
Date Date 
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The APS Journals are copyrighted for the protection of authors and the Society. The Mandatory 
Submission Form serves as the Society's official copyright transfer form. 
Rights of Authors of APS Articles 
For educational purposes only, authors may make copies of their own articles or republish parts 
of these articles (e.g., figures, tables), without charge and without requesting permission, 
provided that full acknowledgement of the source is given in the new work. Authors may not post 
a PDF of their published article on any website; instead, links may be posted to the article on the 
APS journal website. 
Posting of articles or parts of articles is restricted and subject to the conditions below: 
 Theses and dissertations. APS permits whole published articles to be reproduced without 
charge in dissertations and posted to thesis repositories. Full citation is required.  
 Open courseware. Articles, or parts of articles, may be posted to a public access 
courseware website. Permission must be requested from the APS. A copyright fee will 
apply during the first 12 months of the article’s publication by the APS. Full citation is 
required. 
 Institutional websites. The author’s published article (in whole or in part) may not be 
posted to an institutional website, neither at the institutional nor departmental level. This 
exclusion includes, but is not limited to, library websites and national government 
websites. Instead, a link to the article on the APS journal website should be used. (See 
also the APS Policy on Depositing Articles in PMC.) 
 Institutional repositories (non-theses). The author’s published article (in whole or in part) 
may not be posted to any institutional repository. This exclusion includes, but is not 
limited to, library repositories and national government repositories. Instead, a link to the 
APS journal website should be used. (See also the APS Policy on Depositing Articles in 
PMC.) 
 Author’s article in presentations. Authors may use their articles (in whole or in part) for 
presentations (e.g., at meetings and conferences). These presentations may be 
reproduced (e.g., in monographs) on any type of media including, but not limited to, CDs, 
DVDs, and flash drives, for educational use only in materials arising from the meeting or 
conference such as the proceedings of a meeting or conference. A copyright fee will 
apply if there is a charge to the user or if the materials arising are directly or indirectly 
commercially supported. 
 Reuse in another journal before final publication is prohibited. Permission for reuse of an 
article (whether in whole or in part) in another publication is restricted to the final-
published version of the article. If an article is currently published on the APS "publish 
ahead of print" website (Articles in PresS), then the author must wait to request 
permission to reuse the article, or any part of the article, until such time when the article 
appears in final-published form on the APS journal website. 
Authors who do not have access to a subscription and/or who are not APS members may: 
 purchase the article through the pay-per-view option, or 
 purchase a Toll-Free Link from APS, which will allow them to post a link to the APS 
journals website (directly to the article) enabling unlimited free downloads for any user 
accessing the article via this Toll-Free Link. 
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